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Abstract 
Base-mediated formation of N-hydroxy- and N-alkoxyindoles, synthesis of dilemmaones A 
and B, and novel efforts in indole methodology and total synthesis 
 
Katharine E. Lambson 
 A novel and facile base-mediated formation of N-hydroxy- and N-alkoxyindoles from 
2-(2-nitrophenyl)butenoates has been developed. Either potassium tert-butoxide in tert-
butanol or sodium tert-pentoxide in toluene, with or without the subsequent addition of an 
electrophile, can be used to afford an array of N-oxyindoles. The first total syntheses of 
dilemmaones A and B has been accomplished, utilizing Kosugi-Migita-Stille couplings and a 
reductive cyclization of an epoxide precursor with hydrogen gas in the presence of either 
palladium on carbon or platinum oxide as the key steps. Progress toward the total 
synthesis of dilemmaone C using similar methodology has been made. Additional 
methodological work, including screening of a regioselective Mizoroki-Heck reaction to 
form o-nitrostyrenes has been performed. Work toward the synthesis of the 
marinoquinolines has been studied, wherein the key step in precursor synthesis is a one-
pot condensation and cyclization to form the quinoline core.  
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Chapter 1—Base-catalyzed cyclization to form N-alkoxy and N-hydroxyindoles 
I. Introduction 
 N-hydroxy- and N-alkoxyindoles have received an increased amount of attention over 
the last decades for several reasons. Both classes of compounds are present in an array of 
biologically active natural and synthetic products.1 Examples of structurally diverse natural 
compounds that contain either an N-hydroxy- or N-alkoxyindole core include the cytotoxic 
compound stephacidin B (1),2 tetrahydro-β-carboline derivative 2,3 and (R)-paniculidine B 
(3)4 (Figure 1). Additionally, synthetic N-hydroxyindoles such as 4 can act as powerful 
inhibitors of human lactate dehydrogenase isoform A (LDH-A).5 Further, derivatives of 
indole-3-carbinol such as N-alkoxyindole 5 (Figure 1), have been shown to enhance the  I3C-
induced G1 cell cycle arrest of human breast cancer cells.6 N-hydroxy-and N-alkoxyindoles 
have additionally found widespread use as synthetic intermediates, particularly toward the 
production of previously difficult-to-access precursors to indole alkaloids.7  
  
Figure 1. Structures of bioactive natural products 1-3 and synthetic compounds 4 and 5. 
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 There are a number of reported synthetic routes to N-hydroxyindoles. Some 
examples of how these compounds can be formed are by the oxidations of indoles8 and 
indolines,9 reductive cyclizations of 2-(2-nitrophenyl)-aldehydes and -ketones,10 Batcho-
Leimgruber type indole synthesis,11 annulation of nitrosoarenes with alkynes12 and 
rhodium-catalyzed cyclization of arylnitrones13 (Scheme 1). N-alkoxyindoles have only been 
obtained by alkylation of the corresponding N-hydroxyindole derivatives in the presence of 
a base.14, 15  
 
Scheme 1. Previously reported transformations to N-hydroxyindoles. 
Of particular note to this research is the report by Wróbel and Mąkosza of three 
examples of the conversion of tert-butyl 2-(2-nitroaryl)butanoates to N-hydroxyindole 
derivatives in the presence of a strong base.16 One example illustrated in Scheme 2  
showcases the treatment of tert-butyl 2-(5-chloro-2-nitrophenyl)butanoate with sodium 
3 
 
hydroxide in a mixed solvent system to afford tert-butyl 5-chloro-N-hydroxyindole-3-
carboxylate in moderate yield.  
  
Scheme 2. Cyclization of a tert-butyl 2-(5-chloro-2-nitrophenyl)butanoate. 
 
Previously reported in our lab by Dr. Sergei Banini is an example of a related 
cyclization using ethyl 2-(5-methoxy-2-nitrophenyl)butenoate (6).17 The substrate was 
deprotonated with potassium tert-butoxide followed by addition of methyl iodide with the 
intent to trap reactive intermediates (Scheme 3). Interestingly, he isolated only N-
methoxyindole 8 without a trace of other alkylation products. It is noteworthy to mention 
that treatment of the corresponding nitrile, 7, under the same reaction conditions only 
yielded quinoline N-oxide 9 (Scheme 3).  
 
Scheme 3. Cyclization of 6 to N-methoxyindole 8 or of 7 to quinoline N-oxide 9. 
 
In addition to the example of the formation of N-methoxyindole 8 seen in Scheme 3, Dr. Nurul 
Ansari of the Söderberg lab recently described a related cyclization of 2-nitroimine 
derivatives to yield N-methoxybenzimidazoles (Scheme 4).18 Based on the observation that 
2-(2-nitroaryl)butenoates esters can be transformed into N-alkoxyindoles, we sought to 
expand on this transformation. Herein is described the scope and limitations of the direct 
and facile base-mediated synthesis of N-hydroxy- and N-alkoxyindoles. 
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Scheme 4. Formation of N-methoxybenzimidazoles from 2-nitro-N-(2-methyl-1-propen-1-
yl)benzenamines. 
II. Results and Discussion 
 The discovery of a base-mediated formation of N-methoxyindoles was initially 
observed by Dr. Banini during his attempts to probe the effects of nitrile versus ester 
functionalized cyclization precursors. The conditions shown in Scheme 3 were originally 
selected in his efforts to understand the preference of nitrile-substituted precursors for 
cyclization to quinolines, while ester-substituted precursors favored cyclization to N-
alkoxyindoles. With the formation of N-methoxyindole 8 observed under basic, non-catalytic 
conditions, we sought to probe the versatility of this type of transformation. Using precursor 
6 as a model substrate, two additional 2-(2-nitroaryl)butenoates were prepared. Ethyl ester 
10 was synthesized as shown in Scheme 5 according to literature reports, and the 
corresponding methyl ester 11 was prepared according to a previously reported 
methodology.19 
 
Scheme 5. Synthesis of compound 10. 
 Dr. Banini pioneered the work outlined in Table 1. He found that, utilizing the same 
conditions as described in Scheme 3 for the cyclization of ester-derivatives, precursors 10 
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and 11 also reacted to form N-alkoxyindoles. Precursor 10 underwent one-pot cyclization 
and alkylation with methyl iodide to form N-methoxyindole 12 in good yield (Table 1, entry 
1). Methyl ester precursor 11 reacted to form methyl N-methoxy-3-indolecarboxylate (15) 
in 74% yield (Table 1, entry 4). Notably, compound 15 is a naturally-occurring antifungal 
metabolite produced by Wasabi (Wasabia japonica) in response to plant infection.20 This 
alkaloid has also been isolated from the wild crucifer Arabidopsis thaliana.21 The preparation 
of 11 and subsequent transformation to 15 illustrates a novel and efficient method for the 
preparation of this natural product.22 For both precursors 10 and 11, electrophiles other 
than methyl iodide could be used. N-benzyloxyindole 13 and N-allyloxyindole 14 (Table 1, 
entries 2-3) were obtained in good yields from reactions with benzyl bromide and allyl 
bromide, respectively. 
Table 1. Formation of N-alkoxyindoles using potassium tert-butoxide. 
 
Entry 2-(2-nitrophenyl)butanoate R’-X N-alkoxyindolea,b 
  
1 10 (R = Et) Me-I 12 (R = Et, R’ = Me, 84%) 
2 10 (R = Et) Bn-Br 13 (R = Et, R’ = Bn, 78%) 
3 11 (R = Me) Allyl-Br 14 (R = Me, R’ = CH2CH=CH2, 91%) 
4 11 (R = Me) Me-I 15 (R = Me, R’ = Me, 74%) 
 
a General conditions for the preparation of N-alkoxyindoles: 11 equiv. of t-BuOK,  
then 1.5 equiv. of alkylhalide. See experimental section for full details. 
b Yield of pure product isolated after chromatography. 
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Despite the promising data reported in Table 1, the results lacked reproducibility and the 
values given in the Table are the best yields observed from several attempts by Dr. Banini 
and myself.  
In an effort to develop a more consistent means of producing N-alkoxyindoles, we 
explored an alternate hindered base. Sodium tert-pentoxide was selected due to its 
commercial availability in solution and solubility in a variety of organic solvents. Treatment 
of 11 with sodium tert-pentoxide in toluene, in place of potassium tert-butoxide in tert-
butanol, followed by addition of methyl iodide under the reaction conditions described in 
Table 2 (entry 1) did not yield the expected N-methoxyindole 12. Rather, the corresponding 
N-hydroxyindole 19 was obtained as the only observed product. In an effort to encourage 
the formation of 12, the amount of base was sequentially decreased. It was found that under 
all conditions using greater than 2 equivalents of base, the only isolated product was N-
hydroxyindole 19 (Table 2, entries 2-3). Indeed, even when the amount of base was 
decreased further, 19 remained the major product, and N-methoxyindole 12 was isolated in 
only 5% yield as an inseparable mixture with 32% unreacted starting material 10 (Table 2, 
entry 4). To confirm that this type of cyclization does not require the presence of an alkyl 
halide such as MeI to proceed, 10 was reacted with 2.3 equivalents of base without the 
addition of methyl iodide (Table 2, entry 5). As expected, N-hydroxyindole 19 was isolated 
as the sole product, albeit in slightly lower isolated yield. The reason for this observation is 
unknown. 
Further examination of similar alkyl halides (Table 2, entries 6-7) illustrated 
consistent results, in that 19 was isolated as the sole product, while the corresponding N-
alkoxyindoles (13 or 16) were not observed. This formation of N-hydroxyindoles is most 
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similar to the work done by Wróbel and Mąkosza, and yields are comparable across the two 
studies.16 It is worth noting that, using the reaction conditions reported in Table 2, quinoline 
N-oxides were never observed. Despite alkyl halides being unsuitable reagents for the 
preparation of N-alkoxyindoles under these reaction conditions, three alternate 
electrophiles, acetic anhydride, tosyl chloride, and dimethylsulfate (DMS), were screened 
(Table 2, entries 8-10). In these three cases, the reactions all proceeded smoothly to produce 
N-oxygenated indoles 17, 18, and 12. 
Table 2 Optimization of the formation of N-hydroxy- and N-alkoxyindoles from 10.a,b  
 
 
Entry Equiv. base R-X (3 equiv.)  N-Alkoxyindole N-Hydroxyindole 
1  11  MeI                       19 (52%)   
2  5   MeI             19 (51%)   
3  2.3   MeI             19 (52%)   
4  1.1   MeI            12 (5%)c      19 (23%)   
5  2.3   -          19 (42%)   
6  2.3   1-bromohexane          16 (-)       19 (47%)   
7  2.3   BnBr            13 (-)      19 (18%)   
8  2.3   Ac2O            17 (48%)         
9  2.3   TsCl            18 (44%)         
10  2.3   DMSd            12 (54%) 
a See experimental section for details. The methodology for entries 1-4 differs only in the  
 equiv. of base used. 
b Yields are of pure product isolated after chromatography, unless otherwise noted. 
c Inseparable mixture of starting material (32%) and 12 (5%) as determined by 1H-NMR.  
d DMS = dimethyl sulfate. 
 With a consistent means of forming both N-hydroxy- and N-alkoxyindoles thus 
developed, we turned our attention to the tolerance of the reaction conditions to an 
expanded array of substrates. First, we chose to examine the effect of a longer alkyl chain to 
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determine if groups larger than formaldehyde would be eliminated over the course of the 
cyclization (see Scheme 10 for a mechanistic explanation). Our initial approach to forming 
longer chain 2-(2-nitroaryl)alkenoates involved a concurrent Wittig/iodination reaction 
followed by a Kosugi-Migita-Stille coupling (Scheme 6).  
 
Scheme 6. Proposed route to 2-(2-nitroaryl)alkenoates.  
With this in mind, we endeavored to synthesize a variety of ethyl 2-iodo-2-alkenoates using 
a one-pot reaction involving a Wittig reaction23 and olefin iodination.24 The compounds 
made using this methodology are outlined in Table 3.  
 Of the aldehydes screened using this methodology, it was found that the unbranched 
varieties readily condensed to their corresponding alkenoates in good to excellent yields 
(Table 3, entries 1-4). Although branched aldehydes such as cyclohexanecarboxaldehyde 
and 2-phenylpropionaldehyde (Table 3, entries 5 and 6, respectively) condensed to afford 
the desired products, the yields dropped considerably, presumably due to greater steric 
hindrance around the site of condensation. All compounds made using this method (20-25) 
were obtained as inseparable mixtures of E/Z stereoisomers. Additionally, these compounds 
display significant instability in deuterated solvents. It was observed that, upon dissolution 
in chloroform-d for NMR analysis, the solutions (all starting as pale yellow to orange in color) 
turned pink over the course of time ranging from seconds to 30 minutes. Based upon 1H NMR 
analysis, it is surmised that, in solution with chloroform-d, compounds 20-25 degrade to 
their respective dehalogenated derivatives. It is worth mentioning that, although two 
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ketones (acetone and acetophenone) were screened in place of aldehydes (not illustrated in 
Table 3), no condensation was observed for either reaction. 
Table 3. Formation of ethyl-2-iodo-2-alkenoate 
 
Entry                 Aldehyde  Ethyl 2-iodo-2-alkenoatea,b  
1 R = Et  20 [R = Et, 96%]   
2 R = (CH2)2CH3  21 [R = (CH2)2CH3, 83%] 
3 R = (CH2)4CH3  22 [R = (CH2)4CH3, 92%] 
4 R = (CH2)5CH3  23 [R = (CH2)5CH3, 61%] 
5 R = Cyclohexyl  24 [R = Cyclohexyl, 55%] 
6 R = CH(CH3)(Ph)  25 [R = CH(CH3)(Ph), 28%]  
a General conditions for the preparation of iodoalkenoates: 1.25 equiv. N-iodosuccinimide 
(NIS), 3.5 equiv. NaH, 1.0 equiv. triethylphosphonoacetate, then 1.0 equiv. aldehyde. See 
experimental section for full details. 
b Yield of pure product isolated after chromatography. 
With compounds 20-25 in hand, Kosugi-Migita-Stille couplings of each compound with 
tributyl(2-nitrophenyl)stannane were attempted. Unfortunately, in no case was clean 
coupling observed. Rather, results ranged from recovery or decomposition of starting 
material to trace amounts of product contaminated with unknown impurities being 
obtained. Thus, a different means of access to 2-(2-nitroaryl)alkenoates was sought.  
 We next attempted to form these alkenoates in a similar fashion as for the production 
of compound 10. However, upon reaction of either methyl 2-nitrophenylacetate or ethyl 2-
nitrophenylacetate with any aldehyde of longer chain length than acetaldehyde, no reaction 
was observed. Therefore, we envisioned a third route, this time from 2-nitrobenzaldehyde. 
Known α-ketoester 26 was able to be prepared from 2-nitrobenzaldehyde in 4 steps as 
reported by Chorev et al.25 Compound 27 was selected as a representative 2-(2-
nitroaryl)alkenoate for cyclization, and was successfully prepared by a Wittig reaction of 26, 
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albeit in low isolated yield (Scheme 7). Interestingly, compound 10 was not formed under 
similar reaction conditions between 26 and ethyltriphenylphosphonium iodide.  
 
Scheme 7. Formation of and attempted cyclizations of precursor 21. 
With 27 in hand, cyclizations to N-hydroxyindole 28 and N-methoxyindole 15 under 
optimized conditions were attempted. In both cases, no desired product was observed, nor 
was the starting material recovered. Instead, it appears that decomposition occurs over the 
course of the reaction. Based on several additional failed attempts to cyclize 27 under a 
variety of conditions, it was determined that precursors with carbon chains beyond the 
butenoate derivatives were unsuitable substrates for this class of cyclization. 
 The steric and electronic effects of substitution on the aryl ring of the cyclization 
precursor were examined next. Six additional methyl 2-(2-nitroaryl)butenoate derivatives 
(Table 3, compounds 29-34) were synthesized via a Kosugi-Migita-Stille cross coupling of 
substituted 2-nitro-1-bromophenyls with methyl 2-(tributyltin)-2-butenoate.26 All coupling 
products were isolated in low to moderate yield as a mixture of E/Z stereoisomers (Scheme 
8).  
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Scheme 8. Kosugi-Migita-Stille coupling to give 29-34. 
Once compounds 29-34 were isolated, each was subjected to optimized cyclization 
conditions in an attempt to isolate both the N-hydroxy- and N-methoxyindole derivatives. It 
was found that the reaction was highly sensitive to the position of substitution on the 
benzene ring. The derivatives substituted with a methoxy group in the 4- and 5-position (30-
31) yielded their respective N-hydroxy- and N-methoxyindoles in fair to moderate yields 
(Table 4 entries 2A-3B). However, the corresponding 3- and 6-methoxy substituted analogs 
yielded neither N-hydroxy- nor N-methoxyindole products, and no starting material was 
recovered in either case (entries 1A-B and 4A-B). Although it appears that cyclization does 
not tolerate steric encumbrance at the latter positions, we currently are unsure of the 
reasons for that limitation. Ester-substituted butenoates (33 and 34) also successfully 
cyclized to form either the corresponding N-hydroxy- or N-methoxyindole in low to 
moderate yields (Table 4, entries 5A-6B). While the desired N-methoxyindoles were 
obtained, in three of the examples seen in Table 4 (entries 3-B and 5B-6B), pure samples 
could not be isolated, indicating that direct cyclization to N-alkoxyindoles by this method is 
not an ideal approach to these products. However, compounds 38 and 40 could be readily 
produced in excellent isolated yields by the alkylation of the corresponding N-
hydroxyindoles with methyl iodide in the presence of potassium carbonate (Scheme 9). 
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Table 4. Formation of N-hydroxyindoles and N-methoxyindoles from aryl-substituted 
precursors. 
Entry   Precursor    N-hydroxyindolea     N-methoxyindoleb 
   
 
1-A       29 (R = 6-OMe)  not observed         
1-B       29 (R = 6-OMe)      not observed 
 
2-A       30 (R = 5-OMe)  35 (R = 5-OMe, 36%)   
2-B       30 (R = 5-OMe)                 36 (R = 5-OMe, 60%) 
 
3-A       31 (R = 4-OMe)  37 (R = 6-OMe, 42%)   
3-B       31 (R = 4-OMe)                  38 (R = 6-OMe, 46%)c 
 
4-A       32 (R = 3-OMe)  not observed    
4-B       32 (R = 3-OMe)       not observed 
 
5-A       33 (R = 5-CO2Me)  39 (R = 5-CO2Me, 29%)   
5-B       33 (R = 5-CO2Me)             40 (R = 5-CO2Me, 27%)d 
 
6-A       34 (R = 4-CO2Me)  41 (R = 6-CO2Me, 25%)   
6-B       34 (R = 4-CO2Me)             42 (R = 6-CO2Me, 45%)e 
a Conditions use for all 1-6-A entries: 2.3 Equiv. sodium tert-pentoxide. See experimental 
section for details. Yields are reported as pure isolated compounds after chromatography 
unless otherwise noted. 
b Conditions use for all 1-6-B entries: 2.3 Equiv. sodium tert-pentoxide, then 3 equiv. 
dimethyl sulfate. See experimental section for details. Yields are reported as pure isolated 
compounds after chromatography unless otherwise noted. 
c Product was isolated with an inseparable impurity. Compound 38 was confirmed by 
methylation of 37 as described in Scheme 4. 
d Product was isolated with an inseparable impurity. Compound 40 was confirmed by 
methylation of 39 as described in Scheme 4. 
e Isolated as an inseparable mixture, 14.3:1 ratio of product to starting material. Yield and 
ratio determined by 1H NMR. 
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Scheme 9. Formation of N-methoxyindoles 38/40 from N-hydroxyindoles 37/39. 
The base-mediated transformation reported to afford N-hydroxy- and N-
alkoxyindoles can be mechanistically rationalized as illustrated in Scheme 10, and is 
supported by a number of related observations described in the literature.15a, 17, 27, 28 First, 
the deprotonation of 43 will afford 44 as one of several possible resonance forms. 1,7-
electrocyclization of 44 would give rise to 45, which can subsequently undergo ring-opening 
to furnish nitroso-intermediate 46. 1,5-electrocyclization of 46 is plausible based upon 
literature precedence, and would afford intermediate 47. It is then theorized that the loss of 
formaldehyde from 47 would drive the formation of 48. Compound 48 should then readily 
undergo aromatization to 49. Depending on reaction conditions, 49 could either be 
protonated during acidic work-up to yield N-hydroxyindole 50, or react with an added 
electrophile to afford N-alkoxyindole 51.  
Based upon the mechanism outlined, while the major products formed from the two 
pathways are proposed to be either the N-hydroxy- or N-alkoxyindole, in both cases 
formaldehyde should also be lost in the conversion of 47 to 48. For all data entries reported 
in this chapter, formaldehyde was never observed, presumably due to evaporation during 
the removal of solvents. 
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Scheme 10. Proposed mechanism for the formation of N-hydroxy- and N-alkoxyindoles. 
III. Conclusion 
N-hydroxy- and N-alkoxyindoles can be prepared from a base-mediated cyclization of 
2-(2-nitroaryl)-2-butenoate methyl or ethyl esters. N-hydroxyindoles are formed from a 
one-step reaction using sodium tert-pentoxide, and N-alkoxyindoles are formed in a two-
step, one pot reaction using sodium tert-pentoxide followed by addition of an electrophile. 
Cyclization and alkylation using potassium tert-butoxide in tert-butanol can be 
accomplished, but the yields from these reactions are highly variable. Additionally, while it 
has been shown that cyclization conditions are suitable for an array of 2-(2-nitroaryl)-2-
butenoates with steric and electronic variety on either the phenyl ring or added electrophile, 
alkenoates chains longer than the showcased butenoate are not tolerated. This chemistry 
illustrates a novel method for the production of both N-hydroxy- and N-alkoxyindoles. 
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Chapter 2—Total syntheses of dilemmaones A and B and progress toward the 
synthesis of dilemmaone C 
I. Introduction 
In 1997, a variety of specimens were collected off the coast of Cape Town, South Africa 
in order to explore the biomedical potential of South African marine invertebrates. A 
bioassay-directed fractionation of the crude extract from a mixed collection of sponges led 
to the determination of a sphingolipid as the active metabolite. Subsequent 1H NMR and 13C 
NMR investigations of the inactive fractions led to the structural elucidation of dilemmaones 
A (52), B (53), and C (54) (Figure 2).29 These indole alkaloids obtained their unique familial 
name based upon the confusion surrounding their sponge source. However, a process of 
elimination suggested that one of the sponges in the mixed collection, Ectyonanchora 
flabellata, was the source of the dilemmaones. 
 
Figure 2. Structures of the dilemmaones. 
The relatively simple structures of dilemmaones A-C are unusual. To the best of our 
knowledge, no other 2-hydroxymethylene- or 2-methoxymethylene-substituted indoles 
have been isolated and fully characterized to date. In addition to the unique C2-substituent, 
only a few other examples of 6,7-annulated indole natural products have been reported in 
the literature. These include the trikentrins, a family of compounds displaying antibacterial 
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activity that were first isolated by Capon et al from the marine sponge Trikentrion 
flabelliforme.30 Members of this family of compounds include cis-trikentrin A (55), trans-
trikentrin A (56), cis-trikentrin B (57), and trans-trikentrin B (58) (Figure 3), along with 
several other compounds. 
 
Figure 3. Structures of four trikentrins. 
Subsequent to the isolation of the trikentrins, the related trikendiol,31 trikentramine,32 and 
trikentramides33 have all been isolated from sponges belonging to the genus Trikentrion. The 
structurally similar herbindoles were isolated from Axinella sp., an Australian sponge, by 
Scheuer et al.34 Herbindole A (59), herbindole B (60), and herbindole C (61) possess both 
cytotoxic and antifeedant properties (Figure 4).  
 
Figure 4. Structures of the herbindoles. 
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Two related compounds, monomargine (62) and monomarginine (63), are cytotoxic lactams 
isolated from Monocarpia marginalis (Figure 5).35 These tetracyclic compounds possess the 
6,7-annulated indanone-like framework characterized by the dilemmaones.  
 
Figure 5. Structures of monomargine and monomarginine. 
The uncommon structural framework and interesting biological profiles of the 
trikentrins and herbindoles have made them attractive targets for total synthesis. The 
challenges associated with the construction of these complex systems are reflected in the 
many distinct approaches that have been reported for their racemic and enantioselective 
total syntheses. Between 2005-2007, Kerr et al reported the racemic syntheses of herbindole 
A (59), herbindole B (60), cis-trikentrin A (55), and cis-trikentrin B (57) utilizing a Diels-
Alder reaction of quinoid imines.36,37 Previous to those reports, Kanematsu et al reported the 
enantioselective synthesis of cis-trikentrin B (57) which featured an intramolecular Diels-
Alder reaction of an allenic dienamide and stereoselective cleavage of a bicyclic system.38 To 
date, there has been no reported synthesis for any member of the dilemmaone family, 
despite their skeletal resemblance to the trikentrins and herbindoles. Hence, we envisioned 
a route to the dilemmaones showcasing a Watanabe-Cenini-Söderberg cyclization39 as the 
key, terminal step. Herein we report the first total syntheses of dilemmaones A and B and 
progress toward the synthesis of dilemmaone C.  
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II. Results and Discussion 
 Retrosynthetically, dilemmaone B (53) can be constructed from the palladium-
catalyzed N-heterocyclization via Watanabe-Cenini-Söderberg cyclization conditions of o-
nitrostyrene 64. Compound 64 can arise from the Kosugi-Migita-Stille cross-coupling 
between vinyl stannane 65 and an arylhalide (66). Arylindanone 66 could be fashioned 
through the manipulation of commercially-available 2,3-dihydro-5-methylinden-1-one (67). 
 
Scheme 11. Retrosynthetic route to dilemmaone B. 
a. Synthesis of Dilemmaone B 
 Initial work toward dilemmaone B was pioneered by Dr. Christopher Dacko of the 
Söderberg lab. 6-Amino-2,3-dihydro-5-methylinden-1-one (68) was prepared in two steps 
from commercially available 2,3-dihydro-5-methylinden-1-one (67) as reported by Pinna et 
al40 (Scheme 12). As described in Scheme 12, Dr. Dacko originally reported the first 
syntheses of compounds 69, 70, and 71. Optimization work for some of these reactions was 
done by a number of the undergraduates who worked with me. 
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Scheme 12. Initial synthetic approach to dilemmaone B. 
In order to install the nitro group present on C7 of the N-heterocyclization precursor 64, a 
direct nitration of 68 to intermediate 71 was attempted by Dr. Dacko. Lemaire et al have 
reported a one-step nitration of several anilines using 2,3,5,6-tetrabromo-4-methyl-4-
nitrocyclohexa-2,5-dienone (74)41 as a nitronium ion source.42 Utilizing Lemaire’s reaction 
conditions, aniline 68 was seemingly converted to nitroaniline 71. Dr. Dacko confirmed that 
electrophilic aromatic substitution had taken place by the presence of only one aromatic 
proton by 1H NMR. However, upon HRMS analysis, no molecular ion or protonated molecular 
ion was observed for presumed 71. Instead, the HRMS spectrum surprisingly displayed two 
peaks of equal intensity at m/z = 240 and 242, indicating the presence of a bromine atom. 
Thus, Dr. Dacko determined that aniline 68 was not nitrated, but rather brominated by 74 
to give bromoindanone 75 in 59% isolated yield (Scheme 13). Iranpoor and Firouzabadi 
have also reported the nitration of aromatic amines using a AgNO3/Br2, PPh3 reagent 
system.43 Interestingly, Dr. Dacko’s exposure of aniline 68 to these conditions also produced 
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the undesired bromoindanone 75 as the sole reaction product in comparable yield to that 
seen when using Lemaire’s conditions.  
 
Scheme 13. Unexpected bromination of aniline 68 as observed by Dr. Dacko. 
 After the failure of these direct aniline nitration methods, a more traditional route to 
o-nitroaniline 71 was envisioned, involving sequential protection, nitration, and 
deprotection protocol. Aniline 68 was first reacted with acetyl chloride in the presence of 
triethylamine to afford acetanilide 69 in good yield (Scheme 12). Nitration of 69 initially 
proved to be problematic. However, after optimization of the reaction conditions, it was 
discovered that the most effective and concise procedure was through the use of fuming 
HNO3 and concentrated H2SO4 at a reaction temperature of -20 °C for 90 min. Using these 
conditions, nitroindanone 70 was furnished in 70% yield. Subsequent deprotection of 70 to 
o-nitroaniline 71 was attempted using a procedure reported by Pouli et al.44 While these 
conditions did afford nitroaniline 71, yields were inconsistent, with results ranging from 5-
84% isolated yields. It is hypothesized that the wide range of yields are due to the sensitivity 
of the free amine present on 71 to fluctuations in pH during both work-up and 
chromatography. Conversion of 71 to the corresponding halides also proved challenging. 
One pot diazotization and iodination of aromatic amine 71 furnished iodoindanone 72 in 
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moderately good yield, but we were unable to prepare the corresponding bromoindanone 
from 71 using several variations of similar methodology. Next, Kosugi-Migita-Stille cross-
coupling of iodoindanone 72 with (E)-3-(tributylstannyl)-2-propen-1-ol (65) was 
attempted. Under all screened sets of conditions, however, the only observed products were 
dehalogenated nitroindanone 73 or apparent decomposition of 72. Additionally, a 
Sonogashira coupling reaction between 72 and 3-(tert-butyldimethylsiloxy)-1-propyne was 
attempted (not pictured), in an attempt to afford cyclization precursor 64 via a sequential 
coupling and reduction route. However, those reaction conditions also afforded deiodinated 
nitroindanone 73. As iodoindanone 72 was not a good candidate for the access of cyclization 
precursor 64, a different approach was envisioned. 
 The second iteration of the synthesis of dilemmaone B sought to install an aromatic 
halogen prior to nitration, thus avoiding the more circuitous route involving a 
protection/deprotection protocol. To that end, various conditions were screened in an 
attempt to access the desired bromoindanone 76 (Table 5). One pot diazotization and 
bromination of aniline 68 proceeded to afford the desired bromoindanone 76 in 75% yield 
(Table 5, entry 1). In an effort to directly convert commercially available 2,3-dihydro-5-
methylinden-1-one (67) to compound 76, thus effectively eliminating the two-step process 
to afford 68 (Scheme 12), bromination with Br2/AlCl3 (Table 5, entry 2) was attempted, 
however, only the undesired isomer (77) was observed. However, when 67 was subjected 
to conditions based upon those previously reported in our laboratory by Dr. Matthew 
Cummings,45 both the desired bromoindanone (76) and its regioisomer (77) were obtained 
in 32% and 41% isolated yields, respectively (Table 5, entry 3). 
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Table 5. Alternate synthetic access to intermediate 76.a,b 
Entry  Starting Material Reagents  Yield 76 (%)  Yield 77 (%)  
            
1       68   HBr, NaNO2, CuBr      75 
2       67   Br2, AlCl3             12   
3       67   NBSb, H2SO4          32              41 
aValues given are isolated yields. Compounds 76 and 77 are separable by flash column 
chromatography.  
bNBS = N-bromosuccinimide. 
 With 76 in hand, nitration using fuming HNO3 and concentrated H2SO4 was attempted 
(Scheme 14). As expected, two isomers were obtained, the desired nitroindanone 79 as the 
major product (64% isolated yield) and regioisomer 78 as the minor product (17% isolated 
yield). This protocol has allowed for the formation of arylindanone 79 in two steps from a 
commercially-available substrate rather than the originally-proposed six steps. 
Nitroindanone 79 was then subjected to Kosugi-Migita-Stille cross-coupling with (E)-3-
(tributylstannyl)-2-propen-1-ol (65). Upon optimization, we were gratified to find that 
cyclization precursor 64 could be obtained cleanly in 55% yield. Compound 64 was then 
subjected to Watanabe-Cenini-Söderberg reductive cyclization conditions. Despite our 
confidence in conversion of 64 to dilemmaone B (53) as expected, disappointingly, the 
reaction proved to be unsuccessful. Rather, unreacted starting material (64) was recovered 
in all screened sets of conditions for Watanabe-Cenini-Söderberg cyclization. 
23 
 
 
Scheme 14. Second synthetic approach to dilemmaone B. 
Theorizing that the electronics of either the indanone ring or free alcohol might be affecting 
the cyclization, compound 79 was first converted to o-nitrostyrene derivative 81 via Kosugi-
Migita-Stille cross-coupling with (E)-tributyl(3-methoxy-1-propenyl)stannane (80) 
(Scheme 15). 81 was then subjected to acidic reaction conditions with trimethyl 
orthoformate in an effort to synthesize diemethylacetal derivative 82. However, whereas 82 
was not observed, the corresponding methoxyindene (83) was obtained in low yield in 
addition to 11% isolated starting material (81). Despite this unexpected result, we surmised 
that 83 was sufficiently altered in its electronics from compound 64, and thus derivative 83 
was subjected to reductive cyclization conditions. Upon examination of the resultant crude 
1H NMR, no indole product (predicted compound 84) was observed. Rather, chemical shifts 
indicated that 83 had instead reverted to indanone 81.  
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Scheme 15. Synthesis of derivative 83. 
Based upon these results, it was determined that it was unlikely that the electronics of the 
system were affecting the attempted cyclization. This discovery was not particularly 
surprising, as compounds containing unprotected carbonyls such as esters of variety 8546 
and precursors to complex compounds such as cimitrypazepine (86) that contain free 
alcohols47 have cyclized utilizing Watanabe-Cenini-Soderberg conditions without issue in 
our hands (Figure 6).  
 
Figure 6. Two compounds made from reductive cyclizations in the Söderberg lab. 
 In an effort to effect cyclization by different but related means, both o-nitrostyrene 
derivatives that had been synthesized (64 and 81) were subjected to an array of other 
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reductive cyclizations. In addition to the originally-attempted Watanabe-Cenini-Söderberg 
cyclization conditions, TiCl3-promoted reductive cyclization,48 diborane-mediated 
deoxygenation,49 and a modified Cadogan-Sundberg cyclization50 were screened in the 
attempt to convert either 64 or 81 directly to dilemmaone B. In all cases, cyclization to the 
desired natural product was never observed. Instead starting material (64 or 81) was 
recovered. Upon further examination, we were intrigued to find that sterically-encumbered 
o-nitrostyrenes of the type shown in Scheme 16 (non-hydrogen groups on adjacent carbons 
to both the nitro and styrene substituents) have not been reported to proceed for any of the 
aforementioned reductive cyclizations. This discovery highlights a universal limitation for 
reductive N-heterocyclizations of o-nitrostyrenes. Despite not being able to use the desired 
Watanabe-Cenini-Söderberg cyclization conditions toward the dilemmaones, we garnered 
greater understanding of a reaction that has been widely used in the Söderberg lab since Dr. 
James Shriver’s original report in 1997.46 
 
Scheme 16. Sterically encumbered o-nitrostyrenes unable to proceed by reductive 
cyclization. 
Due to the steric encumbrance of the dilemmaone core being unavoidable, and the proposed 
use of our late-stage cyclization of o-nitrostyrene 64 having thus been ruled out as a direct 
means of access to dilemmaone B, an alternate pathway was envisioned. 
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 Compound 64 was transformed into epoxide 89 using 4 equivalents of meta-
chloroperbenzoic acid (m-CPBA). It was anticipated that treatment of 89 with Pd/C and H2 
could result in not only reduction of the nitro group to the corresponding amine, but also a 
subsequent epoxide ring-opening and elimination to afford the desired product, dilemmaone 
B (53). Upon a literature search, to the best of our knowledge, this type of transformation 
has only been reported once, and with very limited scope, demonstrated in the example 
transformation shown in Scheme 17.51  
 
Scheme 17. The catalytic reduction of 87 reported by Watanabe et al. 
Our first attempt of subjecting 34 to conditions similar to Watanabe’s did afford an indole, 
however, upon detailed investigation, the 1H NMR chemical shifts were similar but not in 
agreement with the shifts reported by Faulkner et al for their structural elucidation of 
dilemmaone B. The structure of the isolated product (90) was determined to be the N-
hydroxy analog of dilemmaone B (Scheme 18), which presumably arises from incomplete 
reduction of the nitro group of 89. Additionally, 46% of unreacted starting epoxide 89 was 
isolated. 
 Encouraged by this result, we examined this one-pot reductive cyclization for its 
viability toward the synthesis of dilemmaone B. As our first attempt had yielded 27% of the 
N-hydroxy derivative (90) and had not proceeded to completion, we next attempted to run 
the reaction at elevated temperature (50 °C, Table 6, entry 2). 
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Scheme 18. Synthesis of derivative 90 via sequential epoxidation-reductive cyclization. 
 In this case, the reaction proceeded to completion, but the only observed product was N-
hydroxyindole 90. We next increased the catalyst loading to 5 mol % Pd/C. Upon work-up 
and purification, a new product was observed, however, it was found that over-reduction 
had occurred, yielding 2,4-dimethylindole derivative 91 as the sole product (Table 6, entry 
3). Theorizing that the N-hydroxyindole (90) could be further reduced to the desired indole 
at higher catalyst loading, 90 was subjected to reductive conditions with 5 mol % Pd/C. The 
progress of this reaction was carefully monitored by TLC. After 2 h, we were excited to 
observe that starting material 90 had been completely converted to dilemmaone B (53) in 
27% yield, and no over-reduction to 91 was isolated (Table 6, entry 4). In an effort to obtain 
dilemmaone B directly from the epoxide precursor, we chose to screen the reducing agent 
originally used by Watanabe et al. Upon subjecting 89 to reduction with 2 mol % PtO2 at 50 
°C, and again carefully monitoring the reaction progress by TLC, we were gratified to find 
that dilemmaone B was indeed obtained in 48% isolated yield after 3 h, and neither N-
hydroxyindole 90 nor 2,5-dimethylindole 91 were observed (Table 6, entry 5). It is worth 
noting that, while the identities of N-hydroxyindole 90 and dilemmaone B (53) can be 
confirmed and differentiated via 1H NMR analysis in CDCl3, solubility of both compounds in 
CDCl3 is minimal. Because of this, splitting patterns in that solvent are unclear. However, 
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both 90 and 53 are readily solubilized in DMSO-d6. Interestingly, in contrast to their 1H NMR 
spectral data in CDCl3, chemical shifts in DMSO-d6 are nearly identical, necessitating 
structural confirmation by 1H-15N gHSQC analysis (see Chapter 4 and appendix for details). 
Notably, Faulkner et al did not report all resonances for 13C NMR analysis of dilemmaone B, 
and thus did not provide detailed characterization (HMBC and NOESY) as they had for 
dilemmaone A. Therefore, full NMR analysis was performed for dilemmaone B in DMSO-d6, 
and all data for this compound can be found in Chapter 4 (experimental section) and the 
appendix. 
Table 6. Cyclizations to dilemmaone B.a 
Entry SM Catalyst  Time  Yield 53 (%) Yield 90 (%) Yield 91 (%) 
           
1b 89 2 mol % Pd/C  16 h         27c   
2 89 2 mol % Pd/C  16 h         37   
3 89 5 mol % Pd/C  16 h           16 
4 90 5 mol % Pd/C  2 h       27     
5 89 2 mol % PtO2  3 h       48       
aAll reactions were run in EtOH under 40 psi H2 at 50 °C unless otherwise noted. Yields 
reported are isolated yields after chromatography. See experimental section for details. 
bReaction run at ambient temperature. 
cAlso isolated was 46% unreacted starting material 89. 
b. Synthesis of Dilemmaone A 
 With the dilemmaone B successfully synthesized, we turned our attention to the 
synthesis of dilemmaone A (52), which differs in structure from dilemmaone B only at the 
29 
 
C2 position (dilemmaone A possesses a 2-methoxymethyl whereas dilemmaone B has a 2-
hydroxymethyl substituent). With Kosugi-Migita-Stille coupling adduct 81 in hand (Scheme 
19), epoxidation proceeded smoothly to furnish compound 92 as expected in 51% yield. 
Cyclization precursor 92 was then subjected to reductive conditions using both Pd/C and 
PtO2. 
 
Scheme 19. Synthesis of dilemmaone A.  
While we expected to observe similar results for the reduction of 82 when utilizing 2 mol % 
Pd/C, as for the conversion of 89 to 90 (synthesis of dilemmaone B), interestingly, both 
screened sets of conditions afforded clean conversion of epoxide 92 to dilemmaone A (52). 
While 2 mol % Pd/C consistently led to the production of N-hydroxyindole 90 while 
attempting to form dilemmaone B, the same conditions fully reduced precursor 92 to 
dilemmaone A, and its corresponding N-hydroxyindole was never observed. While the use 
of PtO2 worked cleanly toward the production of both dilemmaones A and B, it seems that 
the use of Pd/C is marginally more effective for the reduction of epoxide 92. Notably, 
dilemmaone A (52) is readily soluble in CDCl3, and 1H NMR chemical shifts match the data 
reported by Faulkner et al. A complete analysis of this natural product can be found in the 
experimental section and appendix. 
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c. Progress Toward the Synthesis of Dilemmaone C 
 With the successful synthesis of dilemmaones A and B accomplished, we turned our 
attention to the synthesis of dilemmaone C. Structurally, the core of dilemmaone C is nearly 
identical to that of dilemmaone A, however, dilemmaone C is the only member of the family 
of compounds that possesses aromatic substitution at C5. Retrosynthetically, we envisioned 
that dilemmaone C could be prepared from compound 93 (Scheme 20), which in turn could 
arise from Kotsugi-Migita-Stille coupling of 94 with 80. This divergent approach was 
selected, as 78 is one of the two isomers formed in the nitration reaction of 76, thus allowing 
for the utilization of both isomers across the syntheses of the dilemmaones. 
 
Scheme 20. Retrosynthesis of dilemmaone C. 
 With this approach in mind, compound 78 was subjected to reductive conditions and 
aniline derivative 95 was obtained in 79% yield (Scheme 21). Subsequently, sequential 
diazotization and hydrolysis of compound 95 was performed, and after optimization of the 
work-up, phenol 96 was obtained in 38% yield. Nitration of 96 was also successful in 
affording 97, albeit in low yield. Further, this transformation has proven to be inconsistent 
in its results, and studies toward a reliable method of nitration are ongoing. With the 
coupling partner in hand, Kotsugi-Migita-Stille coupling was attempted on compound 97 
with 80 under the same conditions used in the synthesis of dilemmaone A. Upon analysis of 
the crude 1H NMR, it appeared that coupling had taken place, as characteristic peaks between 
31 
 
5-7 ppm were observed. However, when purification was attempted, no product was 
isolated, presumably due to the small (under 10 mg) scale on which the reaction had been 
run. 
 
Scheme 21. Attempted synthesis of compound 98. 
 It is believed that, pending successful synthesis of o-nitrostyrene 98, dilemmaone C 
could be synthesized in the same manner as for dilemmaone A (Scheme 22).  
 
Scheme 22. Proposed future steps toward dilemmaone C. 
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Compound 98 should undergo epoxidation to form 99, which should subsequently undergo 
one-pot reduction and cyclization to form the desired indole. These proposed steps are the 
same as for dilemmaones A and B, thus, it is hypothesized that dilemmaone C can be accessed 
with relative ease. 
III. Conclusion 
 The first total syntheses of the naturally occurring tricyclic indole alkaloids, 
dilemmaones A and B, has been successfully accomplished. These compounds can be 
efficiently prepared from 2,3-dihydro-5-methylinden-1-one (67), with both syntheses 
featuring a Kosugi-Migita-Stille coupling and an interesting one-pot reductive cyclization 
using H2 and either a Pd/C or PtO2. As the scope of this reductive cyclization using either 
Pd/C or PtO2 has not yet been widely explored, studies are ongoing in our laboratory to 
determine its versatility. Dilemmaone B (53) was synthesized in 5 steps (overall yield = 
4.0%). From common intermediate 6-Bromo-2,3-dihydro-5-methyl-7-nitroinden-1-one 
(79), dilemmaone A (52) was then synthesized in 3 additional steps (overall yield = 12.2%). 
Work toward the synthesis of dilemmaone C (54), the most highly-substituted member of 
this family of compounds, has begun, and the initial promising results suggest that future 
efforts could lead to its production using a related approach.  
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Chapter 3—Additional methodological and synthetic work toward indole derivatives 
 In addition to the projects discussed in chapters 1 and 2, I have worked on a number 
of additional side-projects. The first of these was a methodology screening for an efficient 
means of access to o-nitrostyrenes that could be subsequently subjected to Watanabe-
Cenini-Söderberg cyclization reactions. The second involved efforts toward the synthesis of 
the naturally occurring marinoquinolines, and was pioneered by two undergraduate 
students under my supervision. The third was a collaborative effort with the West Virginia 
University Division of Forestry and Natural Resources, wherein an exploration of an azide-
alkyne cycloaddition using lignocellulosic materials as a scaffold for copper nanoparticle 
catalysis was performed (not discussed in this report). 
I. Access of substituted o-nitrostyrene derivatives via regioselective Mizoroki-
Heck reactions 
a. Introduction 
 One of the major reactions that has been used over the last two decades by the 
Söderberg lab is the Watanabe-Cenini-Söderberg cyclization.39 This reaction, as illustrated 
in previous chapters, involves the palladium-catalyzed reductive cyclization of o-
nitrostyrene derivatives to afford indoles. The production of these cyclization precursors can 
be accomplished via a vast range of methodologies, including Wittig reactions,52 Suzuki53 and 
Stille54 cross-couplings, and others. An additional reaction that has been widely applied to 
the synthesis of o-nitrostyrenes and related compounds is the Heck reaction.55 Traditionally, 
this reaction involves the reaction of an unsaturated halide or triflate with an alkene in the 
presence of a palladium catalyst and base to afford an array of substituted alkenes. Despite 
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its versatility, the Heck reaction is often limited by preference for coordination with the 
terminal olefinic carbon. While exploring the literature during work on my original research 
proposal, I happened upon a modified Mizoroki-Heck reaction reported by Qin et al, wherein 
the opposite substitution preference was observed. As illustrated in Scheme 23, when aryl 
triflate 100 was reacted with 3-buten-1-ol (101) under modified Heck conditions, there was 
high selectivity for the formation of geminal alkene 102 over its corresponding vicinal 
isomer, 103. 
 
Scheme 23. Modified Mizoroki-Heck reaction as reported by Qin et al. 
 This reactivity was intriguing, as we surmised that it could be applied sequentially, 
preceding a Watanabe-Cenini-Söderberg reaction, to afford indoles with substitution at C3. 
Although there are numerous methods for the production of 3-substituted indoles, this 
would allow for the pre-installation of a substituent at C3 and late-stage cyclization to afford 
the indole. This is in contrast to many of the current methodologies, which rely on 
substitution at the C3 position of an existing indole.57 This approach additionally could 
contribute to the synthetic field, as there are numerous naturally-occurring compounds that 
exhibit C3-substitution of an indole core. For example, the structurally diverse tryptamines 
are a class of monoamine alkaloids an array of neurological and psychedelic effects. 
Tryptamine (104) has been synthesized via the Abramovitch-Shapiro tryptamine synthesis 
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(Scheme 24), which is one such example of desired C3-substitution being introduced after 
the indole core has been created.58 
 
Scheme 24. Abramovitch-Shapiro tryptamine synthesis. 
 In an effort to probe the versatility of this modified and regioselective Mizoroki-Heck 
reaction, we endeavored to screen its applicability toward the production of o-nitrostyrenes, 
particularly those with pre-installed C3 substitution. Here, we report the initial findings of 
this study. 
b. Results and Discussion 
 To initiate our screening of the regioselective Mizoroki-Heck conditions applied to 
nitroaryl triflates, we selected a simple nitroaryltriflate precursor (2-nitrophenyl 
trifluoromethanesulfonate, 105) and subjected it to the reaction conditions reported by Qin 
et al.  
 
Scheme 25. Reaction of 105 under modified Mizoroki-Heck conditions. 
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We were gratified to find that the desired regioisomer, 106, was formed as the major isomer 
in an inseparable mixture with Heck product, 107, in a 6.8:1 ratio and 46% yield (Scheme 
25).  Despite attempting this reaction under a variety of conditions, including different 
solvents, altered catalyst loading, and elevated temperatures, the yields and regioselectivity 
remained comparable or depressed from the originally observed values as shown in Scheme 
25. Interestingly, when the reaction was run under the same conditions, but with the 
temperature increased to 105 °C, the yield and selectivity remained almost identical (47% 
and 6.3:1, respectively), an additional product, o-nitrophenol, was also isolated in 11% yield. 
This suggests that the reaction can be prone to de-triflation under certain conditions, such 
as elevated temperature. Although the results that we obtained were not as promising as 
reported in the literature examples, we were nevertheless encouraged by these preliminary 
findings. Additionally, upon further perusal of Qin’s results, it was discovered that each 
triflate/alkene combination appeared to be specifically tailored to one of several ferrocene-
based ligands. We chose to screen our reactions with only 1,1’-
bis(diphenylphosphino)ferrocene (dppf), which could be a contributing factor to our 
moderately lower yields.  
 With our initial findings proving to be a promising lead, we subsequently subjected a 
number of other aryltriflates to the same conditions. We first sought to confirm the 
preference of the reaction for coupling at the triflate-carbon. To that end, we subjected two 
substrates previously made in our lab by Dr. Ansari59 to the Mizoroki-Heck conditions at 105 
°C (Scheme 26). The elevated temperature was found to be necessary with our selected set 
of reagents in order to avoid recovery of only starting materials. While we did observe the 
formation of the desired geminal alkenes from both substrates 108 and 109, the yields were 
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very poor (7% of 110 and 7% of 112, respectively). Additionally, for substrate 109, as for 
the reaction of 105 with 3-buten-1-ol at elevated temperature, we observed the formation 
of the corresponding phenol (113) in 52% yield.  
 
Scheme 26. Reaction of bromonitroaryl triflates under Mizoroki-Heck conditions. 
While the initial results for these substrates were poor, nevertheless, we were encouraged 
to find that coupling still proceeded, presumably with higher affinity for reaction with the 
aryl-triflate carbon.  
 An additional set of compounds that we attempted Mizoroki-Heck coupling on were 
precursors to two natural products, the tetracyclic indole alkaloids ht-13-A (114) and ht-13-
B (115) (Figure 7).  
 
Figure 7. Structures of indole alkaloids 114 and 115. 
The screened precursors, 116 and 118 (Scheme 27) were originally made by Dr. Jeremiah 
Hubbard in his efforts to synthesize ht-13-A and ht-13-B. Although the route that these 
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precursors were made for ultimately proved unsuccessful, and an alternate pathway led to 
the production of the natural compounds,60.61 it was hypothesized that if intramolecular 
coupling using Mizoroki-Heck conditions were successful, it could alleviate some of the 
difficulties faced by Drs. Hubbard and Zhang, and allow for a more efficient means of access 
to these compounds and others of similar molecular structure.  
 
Scheme 27. Attempted Mizoroki-Heck couplings of 116 and 118.  
Upon subjecting 116 and 118 to coupling conditions, it was found that neither of the 
attempted intramolecular Mizoroki-Heck reactions successfully formed 117 or 119, 
respectively. Rather, examination of the crude 1H NMR spectra indicated that no reaction had 
taken place, and only shifts for the starting materials were observed. Despite these reactions 
not progressing forward as desired, it did serve to reinforce that this methodology appears 
to be highly selective for reaction with aryl triflates, whereas aryl halides seem to be 
unreactive.  
39 
 
 Finally, three additional cyclization precursors were made utilizing this methodology. 
First, known 2-aryl-1-octene 120 was synthesized as reported by Qin et al (Scheme 28).56 
Although 120 was successfully made when utilizing the same reaction conditions as 
reported, in our hands, the reaction yielded only 37% of the desired compound, whereas a 
yield of 83% was reported in the literature. Although we are unsure of the reasons for this 
disparity, it may be that unknown variances in conditions from their reports to ours could 
be a contributing factor to the overall poor to moderate yields seen for all substrates we have 
screened using this chemistry.  
 
Scheme 28. Synthesis of o-nitrostyrene derivative 120. 
The second and third cyclization precursors were made in the reaction of nitroaryl triflate 
105 with coupling partner 121 to screen for the potential of access to tryptophan derivatives 
(Scheme 29).  
 
Scheme 29. Reaction of 105 with amino acid derivative 121. 
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Upon subjection to coupling conditions, we observed an inseparable mixture of desired 
compound 122 and its regioisomer 123 (32%, 3.1:1 mixture of 122:123) and 19% 
unreacted starting material. The yields and regioselectivity for this inseparable mixture of 
the three compounds were determined by 1H NMR. 
Table 7. Formation of indoles from o-nitrostyrenes made using Mizoroki-Heck reactions. 
Entry  Substrate  Conditionsa  Product  Yieldb 
 1  106   Method A    124, 74% 
    
2  112   Method A    125, 0%  
3  120   Method B   126, 37%c 
4  122, 123d  Method C   127, 22% 
         128, 10% 
aMethod A: Pd(OAc)2, PPh3, MeOH/DMF, CO (90 psi), 60 °C, 24 h; Method B: Pd(OAc)2, PPh3, 
CH3CN, CO (90 psi), 100 °C, 24 h; Method C: Pd(dba)2, dppp, 1,10-phen., DMF, CO (90 psi), 
120 °C, 48 h. See experimental section for details. 
bValues reported are isolated yields after purification by chromatography. 
cAlso isolated was 13% unreacted 120. 
dInseparable mixture of 122 and 123 as reported in Scheme 29 was subjected to the 
reaction. 
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 With an assortment of o-nitrostyrene derivatives formed as described above, each 
was subjected to Watanabe-Cenini-Söderberg cyclization conditions. The results for these 
reactions are illustrated in Table 7. Compounds 106 and 120 cyclized as expected, affording 
their respective indole derivatives (124 and 126) in moderate to good yields (Table 7, 
entries 1 and 3). Interestingly, indole 125 was not observed (Table 7, entry 2). It is possible 
that this reaction could be promoted using altered Watanabe-Cenini-Söderberg conditions, 
although only the listed conditions were screened in this preliminary investigation. Finally, 
when the mixed sample of 122 and 123 was subjected to reductive cyclization conditions 
(Table 7, entry 4), we were gratified to find that both expected cyclization products (127 and 
128) were isolated. In particular, this illustrates a promising method of forming tryptophan 
derivatives such as 127 in an expedient fashion.   
c. Conclusion 
 Preliminary work on the applicability of modified Mizoroki-Heck chemistry has been 
performed, and initial results suggest that while this is a possible method for the production 
of indoles with pre-installed C3 substitution, further optimization is needed. This is 
particularly needed for the first, Mizoroki-Heck coupling, reaction in the sequence, as yields 
for the resultant o-nitrostyrenes were consistently observed in the poor-to-moderate range. 
It is believed that further screening of reaction conditions, particularly focused on the ligand 
used, could enhance the yields and regioselectivity of these reactions. A number of indoles 
were also synthesized using this two-step pathway. This is highlighted by the production of 
tryptophan derivative, 127, and suggests that this methodology may hold promise as a 
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means of producing other tryptophan derivatives, which are valuable synthetic building 
blocks. 
II. Progress toward the syntheses of the marinoquinolines 
a. Introduction 
 In 2011, six compounds were isolated from a marine gliding bacteria, Ohtaekwangia 
kribbensis (strain PWU 25) off the coast of Korea.62 Upon analysis, it was found that one of 
these compounds was marinoquinoline A (129), which has previously been isolated from a 
marine bacterium, Rapidithrix thanilandica,63 and was determined to act as an acetylcholine 
esterase inhibitor.64 Along with marinoquinoline A, five novel additional compounds were 
isolated from O. kribbensis: marinoquinolines B-F (130-134), whose structures were 
elucidated using a series of 1D and 2D NMR techniques (Figure 8). 
 
Figure 8. Structures of marinoquinolines A-F. 
 Although the marinoquinolines have only weak activity against a panel of bacteria 
and fungi and modest antiprotozoal activity, they are nevertheless structurally interesting 
and further studies of them and potential structural analogs merit examination. This is 
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highlighted by the variety of methods used to synthesize various members of the 
marinoquinoline family. These approaches have used key steps such as a Bronstad-acid-
mediated arene-ynamide cyclization,65 a palladium-catalyzed cyclization of imines,66 a 
palladium-catalyzed Ullmann cross-coupling,67 and an interesting divergent synthetic 
approach.68 The first concise syntheses of marinoquinolines A-C was accomplished using a 
Morgen-Walls reaction to assemble the quinoline ring by Yao et al in 2012.69 
 We hypothesized that the marinoquinoles could be synthesized using a Henry 
reaction and modified Watanabe-Cenini-Söderberg cyclizations as the key steps in a novel 
and concise approach. This work was largely performed by two of the summer 
undergraduate students who worked under my supervision in the Söderberg lab. Herein are 
presented preliminary results toward the syntheses of these interesting tricyclic alkaloids.  
b. Results and Discussion 
 In an attempt to ascertain proof-of-concept, we first endeavored to create the non-
substituted marinoquinoline core, 135. Retrosynthetically, we envisioned that 135 could be 
formed from the cyclization of nitrostyrene 136, which could in turn be constructed from 
the Henry reaction of 137. Aldehyde 137 could be obtained from 138, which could be 
cyclized using a palladium-catalyzed N-heterocyclization as reported by Dr. Banini17 from 
139. Compound 139 could be obtained by the condensation of commercially available 2-
nitrophenylacetonitrile (140). With these transformations thus proposed, we set out to 
make the marinoquinoline core (135), and pending its success, to synthesize the 
marinoquinolines utilizing similar protocol.  
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Scheme 30. Retrosynthesis of the marinoquinoline core. 
 We first sought to accomplish the condensation of 2-nitrophenylacetonitrile (140) 
with acetaldehyde in the hopes of obtaining compound 139. Upon reaction utilizing similar 
conditions as for the construction of cyclization precursor 10 (Chapter 1), we were initially 
discouraged, as there was no evidence of the expected olefinic quartet in the 1H NMR 
spectrum. However, upon further investigation, we found that instead of the reaction ceasing 
at the production of 139, spontaneous cyclization had occurred to afford 4-
quinolinecarbonitrile-N-oxide (141) in 47% yield (Scheme 31).  
 
Scheme 31. Unexpected formation of N-oxide 141.  
Despite this unexpected product and its modest yield, we were encouraged by the result, as 
this set of conditions negated the need for a two-step condensation and sequential 
45 
 
cyclization pathway as originally envisioned. Additionally, when compared to the related 
condensations that have been performed (as described in Chapter 1), the yields here are 
higher for the equivalent of a two-step process than for the single condensation. We then 
queried whether this reaction required the addition of 18-crown-6 in order to occur. Thus, 
we screened the reaction of compound 140 as before, changing the conditions only by 
omitting the addition of the crown ether. Compound 141 was gratifyingly once again 
obtained, interestingly, in elevated yield (66%, Scheme 31). 
 Encouraged by these results, we next attempted to form the three 
quinolinecarbonitrile-N-oxides that could act as precursors to marinoquinolines A-C using 
similar methodology (Scheme 32).  
 
Scheme 32. Attempted formation of compounds 142, 143, and 144. 
Unfortunately, when substituting any aldehyde for acetaldehyde, none of the cyclization 
products (142-144) were observed, nor were condensation products that are derivatives of 
139 (seen in Scheme 30). Instead, in all cases, whether the reaction was run with or without 
18-crown-6, degradation of the starting material appeared to have occurred. Although 
obtaining quinolinecarbonitrile-N-oxides 142-144 via this reaction would have been a facile 
and direct method, it was noted that these negative results were consistent with what was 
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observed when attempting to form 2-(2-nitroaryl)alkenoates via similar means (Chapter 1), 
in that any aldehyde of longer chain length than formaldehyde or acetaldehyde would not 
undergo condensation.  
 Despite the lack of success in forming substituted quinolinecarbonitrile-N-oxides 
directly from 2-nitrophenylacetonitrile, we hypothesized that they could instead be 
produced from the subjection of unsubstituted quinolinecarbonitrile-N-oxide 141 to 
reaction with Grignard reagents. Further, we expected that when exposed to the reaction 
conditions necessary to facilitate substitution, the N-oxide would reduce to the quinoline. 
Thus, compound 141 was screened for reactivity with three Grignard reagents in the 
attempt to form the corresponding 2-substituted quinoline derivatives (Scheme 33). 
 
Scheme 33. Reaction of 141 with Grignard reagents to form 145-147. 
After screening a variety of methods of reaction, it was found that either using commercially-
purchased and anhydrous Grignard reagents or formation of Grignard reagents in situ 
followed by their direct addition to 141 afforded compounds 145-147 in a wide range of 
yields. Methyl-substituted quinoline 145 was obtained in good yield, however, compounds 
146 and 147 were formed in 17% and 2% yields, respectively, and in both cases unreacted 
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starting material was obtained in significant quantities (20% and 44% recovered, 
respectively).  
 With compounds 145-147 in hand, we next attempted to convert the cyano-group to 
an aldehyde in preparation for the subsequent Henry reaction. However, when compound 
145 was subjected to reaction with diisobutylaluminum hydride (DIBAL-H), reduction to the 
corresponding aldehyde was never observed under any screened conditions (Scheme 34). 
Instead, in all cases, starting material (145) was recovered.  
 
Scheme 34. Attempted reduction of 145. 
We next attempted to access aldehyde 148 by an alternate pathway. By subjecting 
compound 145 to hydrolysis conditions with H2SO4 and H2O, we hoped to obtain the 
corresponding carboxylic acid, which we theorized could be subsequently reduced to obtain 
148. However, upon analysis of the presumed acid, while most of the observed 1H NMR 
peaks were in agreement with literature values, not all matched.70 Additionally, our 
experimental melting point was not in agreement with the literature value of 244 °C. Due to 
these inconclusive data, as well as difficulties encountered while attempting to produce 
aldehyde 148, additional work is needed in order to further the research toward the 
production of the marinoquinolines.  
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c. Conclusion 
 Initial progress has been made toward the syntheses of marinoquinolines A-C. This 
work has showcased an unexpected one-pot condensation/cyclization of 2-
nitrophenylacetonitrile to form quinolinecarbonitrile-N-oxide that can be accomplished 
with or without the use of a crown ether. Although 2-substituted quinolinecarbonitrile-N-
oxides cannot be formed by this one-pot methodology, the respective 2-
alkylquinolinecarbonitriles can be formed from the reaction of quinolinecarbonitrile-N-
oxide with a Grignard reagent in poor to good yields. Thus far, the reduction of the cyano-
group to the corresponding aldehyde has proven to be difficult. Future work may necessitate 
the Henry reaction of an aldehyde prior to installation of substitution at the 2-position in 
order to avoid these unprecedentedly difficult reductions if an alternate means of access to 
the aldehydes cannot be accomplished. Upon successful Henry reactions to the nitrostyrenes 
of variety 136, it is believed that a palladium-catalyzed reductive N-heterocyclization will be 
successful in affording the marinoquinolines.  
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Chapter 4—Experimental Methods 
I. General Procedures  
 All NMR spectra were recorded in either CDCl3 or DMSO-d6 at 400 MHz (1H-NMR) and 
100 MHz (13C-NMR) or 600 MHz(1H-NMR) and 150 MHz (13C-NMR) at ambient temperatures 
unless otherwise stated. The chemical shifts are expressed in δ values relative to SiMe4 (0.0 
ppm, 1H and 13C) or CDCl3 (77.0 ppm, 13C) internal standards. The multiplicity of each 
resonance observed in the 1H NMR spectra are reported as, s = singlet; d = doublet; t = triplet; 
q = quartet; m = multiplet. HRMS data were obtained via electrospray ionization (ESI) with 
an ion trap mass analyzer. Solvents (tetrahydrofuran, dichloromethane, and toluene) were 
purified and dried prior to use via two consecutive columns composed of activated alumina 
and Q5 catalyst on a Glass Contours solvent purification system. Anhydrous N,N-
dimethylformamide and anhydrous N,N-dimethylacetamide were used as received. Hexanes, 
ethyl acetate, and 1,4-dioxane were distilled from calcium hydride. Chemicals prepared 
according to literature procedures have been referenced the first time used. All other 
reagents were obtained from commercial sources and used as received. Reactions were 
performed under a nitrogen atmosphere in oven-dried glassware unless otherwise noted. 
Solvents were removed from reaction mixtures and products on a rotary evaporator at water 
aspirator pressure unless otherwise stated. Melting points (uncorrected) were recorded 
from pure products obtained by chromatography.  
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II. Experimental 
Ethyl 2-(2-nitrophenyl)-2-butenoate (10). Ethyl 2-(2-nitrophenyl)acetate 
(740 mg, 3.60 mmol) and 18-crown-6 (240 mg, 0.90 mmol) were combined in a round-
bottomed flask and the system was purged with N2. THF (9 mL) was added and the solution 
was cooled to -78 °C. A suspension of t-BuOK (440 mg, 3.90 mmol) in THF (6 mL) was added 
dropwise via syringe and solution immediately turned deep blue. Acetaldehyde (1.0 mL, 17.9 
mmol) was added in one portion via syringe, and the resulting solution was stirred at -78 °C 
for 30 min, then warmed to ambient temperature and stirred for 16 h. The reaction was 
quenched by slow addition of saturated aqueous NH4Cl and extracted with EtOAc (3 x 15 
mL). The combined organic phases were dried (MgSO4), and the solvent was removed under 
reduced pressure. The resulting residue was purified by chromatography (hexane/EtOAc 
9:1 then 7:3) to afford 10 (246 mg, 1.05 mmol, 29%) as a yellow oil as a mixture of 
stereoisomers (major/minor = 33.3:1 by 1H NMR). Analytical data from the 33.3:1 mixture 
of stereoisomers: 1H NMR (major isomer) δ 8.14 (dd, J=8.2, 1.2 Hz, 1H), 7.65 (td, J=7.5, 1.3 
Hz, 1H), 7.56-7.49 (m, 1H), 7.27 (dd, J = 7.6, 1.4 Hz, 1H), 7.22 (q, J = 7.2 Hz, 1H), 4.15 (m, 2H), 
1.73 (d, J = 7.2 Hz, 2H), 1.20 (t, J = 7.1 Hz, 3H); 1H NMR (minor isomer, partial data) δ 8.06 
(dd, J = 8.1, 1.2 Hz, 1H), 7.34 (dd, J = 7.6, 1.4 Hz, 1H), 6.41 (q, J = 7.3 Hz, 1H), 2.30 (d, J = 7.3 
Hz, 3H); 13C NMR (major isomer) δ 165.5, 148.7, 139.6, 133.3, 132.8, 132.6, 131.1, 129.0, 
124.9, 61.2, 15.6, 14.2; 13C NMR (minor isomer, partial data) δ 142.8, 133.6, 132.7, 128.7, 
124.5, 60.7, 16.3, 14.1; IR (ATR) 2982, 1709, 1523, 1345, 1267, 1241, 1188, 1047, 1035 cm-
1; HRMS (ESI) calculated for C12H14NO4 (M+H+) 236.0917; found, 236.0930. 
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Ethyl 1-methoxyindole-3-carboxylate (12).  Method A: A solution of 10 (181 
mg, 0.77 mmol) in t-BuOH (2 mL) was added slowly to a pre-formed solution of t-BuOK (1.01 
g, 8.16 mmol) in t-BuOH (3 mL) under a nitrogen atmosphere. The mixture was cooled in an 
ice bath for 10 min. MeI (170 μL, 1.10 mmol) was added drop-wise over a period of 2 min. 
The solution was allowed to warm to ambient temperature and stirred for 3 h. The reaction 
was quenched with a solution of saturated NH4Cl (aqueous, 10 mL) and extracted with 
dichloromethane (3 x 10 mL). The combined organic phases were washed with H2O (3 x 10 
mL) and dried (MgSO4). Solvents were removed under reduced pressure to obtain 12 (141 
mg, 0.65 mmol, 84%) without further purification as a pale yellow oil.  
Method B: Compound 10 (128 mg, 0.54 mmol) was added to a round-bottomed flask, and the 
system was purged with nitrogen gas. Anhydrous PhMe (6 mL) was added via syringe, and 
the solution was cooled to 0 oC. Sodium tert-pentoxide (40% solution in PhMe, 380 L, 1.24 
mmol) was added drop wise, and the solution immediately turned purple then red. The 
solution was stirred at 0 oC for 10 min and dimethyl sulfate (150 L, 1.62 mmol) was added 
via syringe. Solution was warmed to ambient temperature and stirred for 3 h. The resulting 
mixture was quenched with saturated aqueous ammonium chloride and extracted with 
EtOAc (3 x 10 mL). The combined organic phases were dried (MgSO4) and the solvent was 
removed under reduced pressure. The residue was purified by chromatography 
(hexane/EtOAc, 7:3) to afford 12 (64 mg, 0.29 mmol, 54%) as a pale yellow oil. 1H NMR δ 
8.18 (d, J=7.8 Hz, 1H), 7.96 (s, 1H), 7.45 (dd, J=7.8, 1.2 Hz, 1H), 7.32-7.27 (m, 2H), 4.38 (q, 
J=7.2 Hz, 2H), 4.13 (s, 3H), 1.41 (t, J=7.2 Hz, 3H); 13C NMR δ 164.6, 132.0, 128.3, 123.4, 122.8, 
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122.3, 121.8, 108.5, 103.7, 66.6, 59.8, 14.5; IR (ATR) 3118, 2906, 2831, 1686, 1514, 1224, 
1023, 772 cm-1; HRMS (ESI) calculated for C12H14NO3 (M+H+) 220.0968; found, 220.0968. 
Ethyl 1-benzyloxyindole-3-carboxylate (13).  Treatment of 10 (169 mg, 
0.72 mmol) in t-BuOH (3 mL) with t-BuOK (1.01 g, 8.16 mmol) in t-BuOH (3 mL) followed by 
the addition of benzyl bromide (180 μL, 1.08 mmol), as described for 12 (ambient 
temperature, 3 h), gave after work up but without chromatographic purification 13 (166 mg, 
0.56 mmol, 78%) as a pale yellow oil. 1H NMR δ 8.17 (dt, J=7.8, 1.2 Hz, 1H), 7.71 (s, 1H), 7.40-
7.24 (m, 8H), 5.21 (s, 2H), 4.35 (q, J=7.2 Hz, 2H), 1.39 (t, J=7.2 Hz, 3H); 13C NMR δ 164.6, 133.8, 
132.5, 129.6, 129.5, 129.4, 128.8, 123.3, 122.7, 122.3, 121.7, 108.8, 103.4, 81.0, 59.8, 14.5; IR 
(ATR) 3123, 2947, 1698, 1521, 1204, 1082, 740 cm-1; HRMS (ESI) calculated for C18H18NO3 
(M+H+) 296.1287; found, 296.1289. 
 Methyl 1-(2-propen-1-yloxy)indole-3-carboxylate (14).  Treatment of 
1119 (94 mg, 0.43 mmol) in t-BuOH (2 mL) with t-BuOK (600 mg, 4.90 mmol) in t-BuOH (3 
mL) followed by 3-bromo-1-propene (110 μL, 0.65 mmol), as described for 12 (ambient 
temperature, 3 h), gave after chromatography (hexanes/EtOAc, 9:1), 14 (91 mg, 0.39 mmol, 
91%) as a pale yellow oil. 1H NMR δ 8.16 (d, J=7.8 Hz, 1H), 7.92 (s, 1H), 7.46 (d, J=8.1 Hz, 1H), 
7.31 (dd, J=7.5, 1.2 Hz, 1H), 7.27 (dt, J=8.0, 1.2 Hz, 1H), 6.10 (ddt, J=17.0, 10.2, 6.6 Hz, 1H), 
5.37 (dd, J=10.2, 0.9 Hz, 1H), 5.33 (dq, J=17.1, 1.2 Hz, 1H), 4.74 (dt, J=7.2, 1.2 Hz, 2H), 3.91 (s, 
3H); 13C NMR δ 165.0, 132.6, 130.7, 129.5, 123.3, 122.8, 122.4, 121.7, 108.9, 103.1, 79.7, 51.1; 
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IR (ATR) 3126, 2981, 2940, 1693, 1520, 1200, 1081, 1030, 740 cm-1; HRMS (ESI) calculated 
for C13H14NO3 (M+H+) 232.0968; found, 232.0968. 
Methyl 1-methoxyindole-3-carboxylate (15).  Treatment of 11 (176 mg, 
0.80 mmol) in t-BuOH (3 mL) with t-BuOK (1.01 g, 8.16 mmol) in t-BuOH (3 mL) followed by 
addition of MeI (200 μL, 1.20 mmol), as described for 12 (ambient temperature, 3 h), gave 
after work up but without chromatographic purification 1 (121 mg, 0.59 mmol, 74%) as a 
pale yellow oil. 1H NMR δ 8.18 (dt, J=7.8, 1.2 Hz, 1H), 7.96 (s, 1H), 7.46 (dt, J=7.8, 1.2 Hz, 1H), 
7.33-7.26 (m, 2H), 4.14 (s, 3H), 3.91 (s, 3H); 13C NMR δ 165.0, 132.0, 128.3, 123.4, 122.8, 
122.4, 121.8, 108.6, 103.4, 66.6, 51.1. 
Ethyl 1-acetoxyindole-3-carboxylate (17). Compound 10 (106 mg, 0.45 
mmol) was added to a round-bottomed flask, and the system was purged with N2. Anhydrous 
PhMe (5 mL) was added via syringe, and the solution and cooled to 0 °C.  Sodium tert-
pentoxide (40% solution in PhMe, 310 μL, 1.04 mmol) was added drop wise, and the solution 
immediately turned purple then red. This solution stirred at 0 °C for 10 min and acetic 
anhydride (130 μL, 1.35 mmol) was added via syringe. Solution was warmed to ambient 
temperature and stirred for 3 h. The resultant mixture was quenched by addition of 
saturated aqueous ammonium chloride and extracted with EtOAc (3x10 mL). The combined 
organics were dried (MgSO4) and the solvent was removed under reduced pressure. The 
resulting residue was purified by chromatography (hexane/EtOAc 7:3) to afford 17 (53 mg, 
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0.21 mmol, 48%) as an orange oil. 1H NMR δ 8.23-8.17 (m, 1H), 7.83 (s, 1H), 7.32-7.28 (m, 
2H), 7.23-7.20 (m, 1H), 4.38 (q, J = 7.1 Hz, 2H), 2,43 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H); 13C NMR 
δ 168.0, 164.6, 133.4, 129.9, 124.1, 122.9, 122.8, 122.0, 108.4, 105.3, 60.2, 18.1, 14.7; IR 
(ATR) 3130, 2967, 1809, 1691, 1525, 1206, 1164 cm-1; HRMS (ESI) calculated for C13H14NO4 
(M+H+) 248.0917; found, 248.09294. 
Ethyl 1-tosyloxyindole-3-carboxylate (18).  Treatment of 10 (91 mg, 0.39 
mmol) in PhMe (5 mL) with sodium tert-pentoxide (40% solution in PhMe, 270 μL, 0.90 
mmol) followed by p-toulenesulfonyl chloride (223 mg, 1.17 mmol) as described for 17 
(ambient temperature, 3 h) gave after chromatography (hexane/EtOAc 7:3) 18 (62 mg, 0.17 
mmol, 44%) as an oil which solidified upon standing to an orange solid. mp = 87-90 °C; 1H 
NMR δ 8.11 (d, J = 7.9 Hz, 1H), 7.75 (d, J = 8.4 Hz, 2H), 7.67 (s, 1H), 7.32 (d, J = 8.0 Hz, 2H), 
7.21 (t, J = 7.6 Hz, 1H), 7.12 (t, J = 7.7 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 
2.45 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H); 13C NMR δ 164.2, 147.8, 134.1, 130.7, 130.6, 129.7, 129.6, 
124.3, 123.2, 122.5, 121.7, 109.3, 106.5, 60.4, 22.0, 14.6; IR (ATR) 2926, 1707, 1526, 1389, 
1192, 1075 cm -1; HRMS (ESI) calculated for C18H18NO5S (M+H+) 360.0900; found, 360.0913. 
Ethyl 1-hydroxyindole-3-carboxylate (19).10c Compound 10 (120 mg, 0.51 
mmol) was added to a round-bottomed flask, and the system was purged with N2. Anhydrous 
PhMe (6 mL) was added via syringe, and the solution and cooled to 0 °C. Sodium tert-
pentoxide (40% solution in PhMe, 350 μL, 1.17 mmol) was added dropwise, and the solution 
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immediately turned purple. The mixture was allowed to warm to ambient temperature and 
stirred for 3 h. The resultant mixture was quenched by addition of saturated aqueous 
ammonium chloride and extracted with EtOAc (3 x 10 mL). The combined organic phases 
were dried (MgSO4) and the solvent was removed under reduced pressure. The resulting 
residue was purified by chromatography (hexane/EtOAc 1:1) to afford 19 (44 mg, 0.22 
mmol, 42%) as an orange oil. 1H NMR δ 9.47 (s, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.64 (s, 1H), 7.46 
(d, J = 7.2 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.19 (d, J = 7.2 Hz, 1H), 4.24 (q, J = 7.0 Hz, 2H), 1.32 
(t, J = 7.1, 3H); 13C NMR δ 167.0, 134.0, 130.8, 123.4, 122.6, 122.5, 121.2, 109.4, 102.0.  
  Ethyl 2-iodo-2-pentenoate (20). N-iodosuccinimide (NIS, 1.18 g, 5.24 
mmol) and NaH (60% dispersion in mineral oil, 590 mg, 14.7 mmol) were suspended in 
tetrahydrofuran (THF, 15 mL). Triethylphosphonoacetate (830 μL, 4.19 mmol) was added 
dropwise, and solution stirred at ambient temperature for 1 h. Propionaldehyde (300 μL, 
4.19 mmol) was added dropwise via syringe, and the solution stirred at ambient temperature 
for an additional 1 h. The reaction was quenched by slow addition of saturated aqueous 
NH4Cl and extracted with ethyl acetate (3 x 15 mL). The combined organics were washed 
sequentially with saturated aqueous NaHSO3 (15 mL) and H2O (15 mL), dried over MgSO4, 
and the solvent was removed under reduced pressure. The resulting residue was purified by 
chromatography over a short plug of silica (hexane/EtOAc 1:1) to afford 20 (1.02 g, 4.03 
mmol, 96%) as a pale yellow oil, mixture of stereoisomers (major:minor = 2.6:1 by 1H NMR). 
Analytical data from the 2.6:1 mixture of stereoisomers: 1H NMR (400 MHz, chloroform-d, 
major isomer) δ 7.19 (t, J = 7.0 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 2.32 (m, 2H), 1.33 (t, J = 7.2 
Hz, 3H), 1.11 (t, J = 7.3 Hz, 3H); 1H NMR (400 MHz, chloroform-d, minor isomer, partial data) 
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δ 6.89 (t, J = 7.6 Hz, 1H), 4.19 (m, 2H), 2.47 (m, 2H); 13C NMR (101 MHz, chloroform-d, major 
isomer) δ 162.9, 154.3, 94.6, 62.5, 30.5, 14.4, 11.8; 13C NMR (101 MHz, chloroform-d, minor 
isomer) δ 163.8, 157.3, 84.2, 62.1, 29.6, 13.1, 12.1. 
  Ethyl 2-iodo-2-hexenoate (21). n-Butyraldehyde (500 μL, 5.57 mmol) 
was reacted with triethylphosphonoacetate (1.10 mL, 5.57 mmol), NIS (1.57 g, 6.96 mmol), 
and NaH (60% dispersion in mineral oil, 780 mg, 19.5 mmol) in THF (20 mL) as described 
for 20. After purification over a short plug of silica gel (hexanes:EtOAc 1:1), 21 (1.24 g, 4.64 
mmol, 83%) was obtained as a pale yellow oil, mixture of stereoisomers (major:minor = 2.1:1 
by 1H NMR). Analytical data from the 2.1:1 mixture of stereoisomers: 1H NMR (400 MHz, 
chloroform-d, major isomer) δ 7.20 (t, J = 7.0 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 2.29 (q, J = 7.3 
Hz, 2H), 1.59-1.52 (m, 2H), 1.33 (t, J = 7.2 Hz, 3H), 0.99 (t, J = 7.4 Hz, 3H); 1H NMR (400 MHz, 
chloroform-d, minor isomer, partial data) δ 6.89 (t, J = 7.8 Hz, 1H), 4.22-4.15 (m, 2H), 2.43 (q, 
J = 7.6 Hz, 2H), 1.47 (m, 2H); 13C NMR (101 MHz, chloroform-d, major isomer) δ 171.0, 152.9, 
95.2, 60.2, 38.8, 29.6, 20.8, 14.1; 13C NMR (101 MHz, chloroform-d, minor isomer) δ 166.2, 
155.7, 84.5, 60.0, 35.2, 29.3, 20.9, 13.7. 
  Ethyl 2-iodo-2-octenoate (22). Hexanal (500 μL, 4.08 mmol) was 
reacted with triethylphosphonoacetate (810 μL, 4.08 mmol), NIS (1.15 g, 5.10 mmol), and 
NaH (60% dispersion in mineral oil, 570 mg, 14.3 mmol) in THF (15 mL) as described for 20. 
After purification over a short plug of silica gel (hexanes:EtOAc 1:1), 22 (1.12 g, 3.77 mmol, 
92%) was obtained as a pale yellow oil, mixture of stereoisomers (major:minor = 3.6:1 by 1H 
NMR). Analytical data from the 3.6:1 mixture of stereoisomers: 1H NMR (400 MHz, 
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chloroform-d, major isomer) δ 7.20 (t, J = 7.0 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 2.36-2.27 (m, 
2H), 1.35-1.25 (m, 9H), 0.92-0.87 (m, 3H); 1H NMR (400 MHz, chloroform-d, minor isomer, 
partial data) δ 6.90 (t, J = 7.7 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.45 (q, J = 7.6 Hz, 2H); 13C NMR 
(101 MHz, chloroform-d, major isomer) δ 162.8, 153.2, 95.1, 62.5, 36.9, 31.3, 29.6, 27.1, 22.4, 
13.9; 13C NMR (101 MHz, chloroform-d, minor isomer, partial data) δ 163.8, 149.4, 84.4, 62.0, 
31.2, 29.3, 27.0, 22.3, 14.1; IR (ATR) 2955, 2925, 1717, 1464, 1367, 1242, 1175, 1038 cm-1; 
HRMS (ESI) calculated for C10H18IO2 (M+H+) 297.03; found, 297.0346. 
  Ethyl 2-iodo-2-nonenoate (23). Heptanal (500 μL, 3.55 mmol) 
was reacted with triethylphosphonoacetate (700 μL, 3.55 mmol), NIS (1.00 g, 4.44 mmol), 
and NaH (60% dispersion in mineral oil, 500 mg, 12.4 mmol) in THF (15 mL) as described 
for 20. After purification over a short plug of silica gel (hexanes:EtOAc 1:1), 23 (670 mg, 2.16 
mmol, 61%) was obtained as a pale yellow oil, mixture of stereoisomers (major:minor = 6.3:1 
by 1H NMR). Analytical data from the 6.3:1 mixture of stereoisomers: 1H NMR (400 MHz, 
chloroform-d, major isomer) δ 7.20 (t, J = 7.0 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 2.31 (q, J = 7.2 
Hz, 2H), 1.35-1.31 (m, 11H), 0.90-0.88 (m, 3H); 1H NMR (400 MHz, chloroform-d, minor 
isomer, partial data) δ 6.90 (t, J = 7.7 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.45 (q, J = 7.6 Hz, 2H); 
13C NMR (101 MHz, chloroform-d, major isomer) δ 163.0, 153.3, 95.1, 62.6, 37.1, 31.6, 29.7, 
29.0, 27.4, 22.5, 14.1; 13C NMR (101 MHz, chloroform-d, minor isomer, partial data) δ 156.2, 
93.4, 62.1, 28.8, 22.7, 14.2. 
  Ethyl 3-cyclohexyl-2-iodopropenoate (24). 
Cyclohexanecarboxaldehyde (500 μL, 4.13 mmol) was reacted with 
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triethylphosphonoacetate (820 μL, 4.13 mmol), NIS (1.16 g, 5.16 mmol), and NaH (60% 
dispersion in mineral oil, 580 mg, 14.5 mmol) in THF (15 mL) as described for 20. After 
purification over a short plug of silica gel (hexanes:EtOAc 1:1), 24 (705 mg, 2.29 mmol, 55%) 
was obtained as a pale yellow oil, mixture of stereoisomers (major:minor = 4.5:1 by 1H NMR). 
Analytical data from the 4.5:1 mixture of stereoisomers: 1H NMR (400 MHz, chloroform-d, 
major isomer) δ 6.98 (d, J = 9.0 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 2.49-2.37 (m, 1H), 1.77-1.73 
(m, 5H), 1.36-1.30 (m, 8H); 1H NMR (400 MHz, chloroform-d, minor isomer, partial data) δ 
6.71 (d, J = 10.0 Hz, 1H), 2.91-2.78 (m, 1H); 13C NMR (101 MHz, chloroform-d, major isomer) 
δ 163.1, 157.1, 92.7, 62.6, 45.9, 32.1, 30.5, 25.3, 14.2; 13C NMR (101 MHz, chloroform-d, minor 
isomer, partial data) δ 160.5, 62.1, 31.9, 29.7, 25.7, 14.1. 
  Ethyl 2-iodo-4-phenylpentenoate (25). 2-Phenylpropionaldehyde 
(500 μL, 3.74 mmol) was reacted with triethylphosphonoacetate (740 μL, 3.74 mmol), NIS 
(1.05 g, 4.68 mmol), and NaH (60% dispersion in mineral oil, 520 mg, 13.1 mmol) in THF (15 
mL) as described for 20. After purification over a short plug of silica gel (hexanes:EtOAc 1:1), 
25 (348 mg, 1.06 mmol, 28%) was obtained as a yellow oil, mixture of stereoisomers 
(major:minor = 2.1:1 by 1H NMR).Analytical data from the 4.8:1 mixture of stereoisomers: 
1H NMR (400 MHz, chloroform-d, major isomer) δ 7.33-7.30 (m, 3H), 7.24-7.18 (m, 2H), 7.11 
(dd, J = 15.7, 6.7 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.62 (m, 1H), 1.44 (t, J = 7.0 Hz, 3H), 1.28 (d, 
J = 7.1 Hz, 3H); 1H NMR (400 MHz, chloroform-d, minor isomer, partial data) δ 6.91 (d, J = 
10.4 Hz, 1H), 3.76-3.71 (m, 1H); 13C NMR (101 MHz, chloroform-d, major isomer) δ 201.1, 
166.8, 152.6, 143.3, 129.1, 128.7, 127.3, 126.7, 120.1, 60.3, 42.0, 20.2, 14.2; 13C NMR (101 
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MHz, chloroform-d, minor isomer) δ 202.1, 163.0, 155.8, 142.4, 128.8, 127.2, 127.0, 62.8, 
46.9, 19.5, 14.6; IR (ATR) 3027, 2976, 1715, 1493, 1452, 1367, 1264, 1173, 1028, 759 cm-1; 
HRMS (ESI) calculated for C10H18IO2 (M+H+) 337.07; found, 337.1796. 
Methyl 2-(2-nitrophenyl)-2-hexenoate (27).  Under an nitrogen 
atmosphere, butyltriphenylphosphonium bromide (350 mg, 0.87 mmol) was dissolved in 
THF (3 mL) and the solution was cooled to 0 °C. BuLi (2.5 M, 350 μL, 0.87 mmol) was added 
drop wise via syringe and the resultant orange solution was stirred at 0 °C for 1 h. Compound 
26 (150 mg, 0.72 mmol) dissolved in THF (2 mL) was added via syringe, and solution was 
warmed to ambient temperature and stirred for 17 h. The reaction mixture was quenched 
by addition of H2O and extracted with EtOAc (3 x 10 mL). The combined organic phases were 
dried (MgSO4) and solvent was removed under reduced pressure. The resultant residue was 
purified by chromatography (hexane/EtOAc 9:1) to afford 27 (43 mg, 0.17 mmol, 24%) as a 
pale yellow oil as a mixture of stereoisomers (major/minor = 11.6:1 by 1H NMR). Analytical 
data from the 11.6:1 mixture of stereoisomers: 1H NMR (major isomer) δ 8.14 (dd, J = 8.2, 
1.3 Hz, 1H), 7.64 (td, J = 7.5, 1.3 Hz, 1H), 7.55-7.48 (m, 1H), 7.25 (d, J = 7.8 Hz, 1H), 7.12 (t, J 
= 7.8 Hz, 1H), 3.70 (s, 3H), 2.04-1.89 (m, 2H), 1.45 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H); 1H NMR 
(minor isomer, partial data) δ 6.27 (t, J = 7.6 Hz, 1H), 2.82-2.72 (m, 2H); 13C NMR (major 
isomer) δ 166.2, 148.7, 145.0, 133.4, 132.7, 131.4, 129.0, 124.9, 52.3, 31.8, 22.0, 13.9. 
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Methyl 2-(6-methoxy-2-nitrophenyl)-2-butenoate (29).  Under an 
nitrogen atmosphere, methyl 2-(tributyltin)-2-butenoate26 (232 mg, 0.59 mmol) in PhMe (2 
mL) was added via syringe to a solution of 2-bromo-1-methoxy-3-nitrobenzene (125 mg, 
0.54 mmol), Pd(PPh3)4 (62 mg, 0.054 mmol) in PhMe (3 mL). The solution was heated to 
reflux for 16 h, then cooled to ambient temperature, quenched with H2O, and extracted with 
EtOAc (3 x 10 mL). The combined organic phases were washed with brine (3 x 10 mL), dried 
(MgSO4), and the solvent was removed under reduced pressure. The resulting residue was 
purified by chromatography (hexane/EtOAc 9:1 then 7:3) to afford 29 (35 mg, 0.14 mmol, 
26%) as an orange oil as a mixture of stereoisomers (major/minor = 2.3:1 by 1H NMR). 
Analytical data from the 2.3:1 mixture of stereoisomers: 1H NMR (major isomer) δ 7.63 (d, J 
= 8.2 Hz, 1H), 7.46 (t, J = 8.4 Hz, 1H), 7.20 (dd, J = 14.2 7.6 Hz, 2H), 3.84 (s, 3H), 3.71 (s, 3H), 
1.58 (d, J = 7.2 Hz, 3H); 1H NMR (minor isomer, partial data) δ 7.39 (t, J = 8.2 Hz, 1H), 7.11 (d, 
J = 8.0 Hz, 1H), 6.15 (q, J = 7.3 Hz, 1H), 3.83 (s, 3H), 2.23 (d, J = 7.3 Hz, 3H); 13C NMR (major 
isomer) δ 166.3, 157.8, 150.0, 141.5, 129.6, 126.8, 119.9, 116.3, 115.4, 56.6, 52.2, 15.6; 13C 
NMR (minor isomer) δ 166.1, 158.2, 150.2, 143.6, 129.0, 125.6, 123.9, 115.9, 115.0, 57.2, 
51.8, 16.3; IR (ATR) 2951, 1718, 1527, 1355, 1266, 1200, 1053; HRMS (ESI) calculated for 
C12H14NO5 (M+H+) 252.0866; found, 252.0878. 
Methyl 2-(5-methoxy-2-nitrophenyl)-2-butenoate (30).  Treatment 
of 1-bromo-5-methoxy-2-nitrobenzene (270 mg, 1.17 mmol) in PhMe (6 mL) with Pd(PPh3)4 
(140 mg, 0.12 mmol) and methyl 2-(tributyltin)-2-butenoate (500 mg, 1.29 mmol), as 
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described for 29 (reflux, 16 h), gave after chromatography (hexane/EtOAc 9:1 then 7:3) 30 
(117 mg, 0.47 mmol, 40%) as an orange oil as a mixture of stereoisomers (major/minor = 
15.9:1 by 1H NMR). Analytical data from the 15.9:1 mixture of stereoisomers: 1H NMR (major 
isomer) δ 8.22 (d, J = 9.1 Hz, 1H), 7.17 (q, J = 7.2 Hz, 1H), 6.97 (dd, J = 9.2, 2.8 Hz, 1H), 6.70 
(d, J = 2.8 Hz, 1H), 3.90 (s, 3H), 3.69 (s, 3H), 1.72 (d, J = 7.2 Hz, 3H); 1H NMR (minor isomer, 
partial data) δ 8.14 (d, J = 9.1 Hz, 1H), 6.92 (dd, J = 9.1, 2.8 Hz, 1H), 6.78 (d, J = 2.8 Hz, 1H), 
6.35 (q, J = 7.3 Hz, 1H), 3.65 (s, 3H), 2.30-2.27 (m, 3H); 13C NMR (major isomer) δ 166.0, 
163.3, 141.5, 139.0, 133.8, 132.9, 127.6, 117.8, 113.4, 56.1, 52.2, 15.5; 13C NMR (minor 
isomer, partial data) δ 165.5, 163.6, 142.1, 138.2, 135.3, 132.8, 127.3, 117.9, 113.2, 51.6, 16.1; 
IR (ATR) 2950, 1713, 1576, 1509, 1336, 1233, 1041 cm-1; HRMS (ESI) calculated for 
C12H14NO5 (M+H+) 252.0866; found, 252.0879. 
Methyl 2-(4-methoxy-2-nitrophenyl)-2-butenoate (31).  Treatment 
of 1-bromo-4-methoxy-2-nitrobenzene (126 mg, 0.55 mmol) in PhMe (5 mL) with Pd(PPh3)4 
(64 mg, 0.06 mmol), and methyl 2-(tributyltin)-2-butenoate (234 mg, 0.60 mmol), as 
described for 29 (reflux, 16 h), gave after chromatography (hexane/EtOAc 9:1 then 7:3) 31 
(59 mg, 0.24 mmol, 43%) as an orange oil, mixture of stereoisomers (major/minor = 11.7:1 
by 1H NMR). Analytical data from the 11.7:1 mixture of stereoisomers: 1H NMR (major 
isomer) δ 7.66 (s, 1H), 7.21-7.12 (m, 3H), 3.91 (s, 3H), 3.69 (s, 3H), 1.71 (d, J = 7.1 Hz, 3H); 1H 
NMR (minor isomer, partial data) δ 7.58 (s, 1H), 6.38-6.29 (m, 1H), 3.89 (s, 3H), 3.65 (s, 3H), 
2.27 (d, J = 7.8 Hz, 3H); 13C NMR (major isomer) δ 166.4, 159.7, 149.1, 139.8, 133.5, 132.0, 
123.0, 120.0, 109.5, 56.1, 52.3, 15.7; 13C NMR (minor isomer) δ 165.9, 159.5, 148.3, 142.4, 
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135.6, 131.7, 121.5, 120.2, 109.4, 56.2, 51.7, 16.3; IR (ATR) 2951, 1720, 1530, 1351, 1235, 
1032 cm-1; HRMS (ESI) calculated for C12H14NO5 (M+H+) 252.0866; found, 252.0878. 
Methyl 2-(3-methoxy-2-nitrophenyl)-2-butenoate (32).  Treatment of 1-
bromo-3-methoxy-2-nitrobenzene (148 mg, 0.64 mmol) in PhMe (5 mL) with Pd(PPh3)4 (74 
mg, 0.06 mmol), and methyl 2-(tributyltin)-2-butenoate (500 mg, 1.29 mmol), as described 
for 29 (reflux, 48 h), gave after chromatography (hexane/EtOAc 7:3 then 1:1) 32 (76 mg, 
0.30 mmol, 47%) as an orange oil, mixture of stereoisomers (major:minor = 6.0/1 by 1H 
NMR). Analytical data from the 6.0:1 mixture of stereoisomers: 1H NMR (major isomer) δ 
7.45 (t, J = 8.1 Hz, 1H), 7.26 (q, J = 7.2 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 6.79 (d, J = 7.7 Hz, 1H), 
3.93 (s, 3H), 3.71 (s, 3H), 1.69 (d, J = 7.2 Hz); 1H NMR (minor isomer) δ 7.40 (t, J = 8.1 Hz, 1H), 
7.01 (d, J = 8.5 Hz, 1H), 6.87 (d, J = 7.8 Hz, 1H), 6.38 (q, J = 7.3 Hz, 1H), 3.91 (s, 3H), 3.70 (s, 
3H), 2.19 (d, J = 7.3 Hz, 3H); 13C NMR (major isomer) δ 165.9, 151.2, 144.1, 133.8, 131.3, 
130.0, 129.6, 122.7, 112.3, 56.6, 52.4, 15.8; 13C NMR (minor isomer, partial data) δ 151.1, 
145.1, 131.1, 129.1, 122.8, 112.0, 56.6, 51.9, 16.4; IR (ATR) 2951, 1718, 1578, 1530, 1434, 
1369, 1263, 1224, 1038 cm-1; HRMS (ESI) calculated for C12H14NO5 (M+H+) 252.0866; found, 
252.0878. 
Methyl 2-(5-carbomethoxy-2-nitrophenyl)-2-butenoate (33). 
Under a nitrogen atmosphere, methyl 2-(tributyltin)-2-butenoate (500 mg, 1.29 mmol) in 
PhMe (4 mL) was added via syringe to a solution of 3-bromo-4-nitrobenzoic acid methyl 
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ester (303 mg, 1.17 mmol), PdCl2(PPh3)2 (16 mg, 0.02 mmol), PPh3 (12 mg, 0.05 mmol) in 
PhMe (8 mL). The solution was heated to reflux for 24 h, then cooled to ambient temperature, 
quenched with H2O, and extracted with EtOAc (3 x 10 mL). The combined organics were 
washed with brine (3 x 10 mL), dried (MgSO4), and the solvent was removed under reduced 
pressure. The resulting residue was purified by chromatography (hexane/EtOAc 9:1 then 
7:3 gradient) to afford 33 (180 mg, 0.65 mmol, 55%) as a pale orange oil, mixture of 
stereoisomers (major/minor = 5.5:1 by 1H NMR). Analytical data from the 5.5:1 mixture of 
stereoisomers: 1H NMR (major isomer) δ 8.17 (s, 2H), 7.94 (s, 1H), 7.28 (q, J = 7.3 Hz, 1H), 
3.97 (s, 3H), 3.70 (s, 3H), 1.74 (d, J = 7.3 Hz, 3H); 1H NMR (minor isomer, partial data) δ 8.01 
(s, 1H), 6.48 (q, J = 7.6 Hz, 1H), 3.66 (s, 3H), 2.32 (d, J = 7.3 Hz, 3H); 13C NMR (major isomer) 
δ 165.7, 165.2, 151.2, 144.4, 141.1, 134.3, 134.1, 131.3, 130.2, 125.1, 53.1, 52.4, 15.8; 13C NMR 
(minor isomer, partial data) δ 141.9, 134.5, 133.9, 131.2, 129.9, 124.7, 52.2, 51.8, 16.5; IR 
(ATR) 2954, 1726, 1529, 1437, 1347, 1283, 1250, 1116 cm-1; HRMS (ESI) calculated for 
C13H14NO6 (M+H+) 280.0972; found, 280.0828. 
Methyl 2-(4-carbomethoxy-2-nitrophenyl)-2-butenoate (34).  
Treatment of 4-bromo-3-nitrobenzoic acid methyl ester (97 mg, 0.38 mmol) in PhMe (5 mL) 
with Pd(PPh3)4 (43 mg, 0.04 mmol), and methyl 2-(tributyltin)-2-butenoate (160 mg, 0.41 
mmol) as described for 29 (reflux, 24 h) gave after chromatography (hexane/EtOAc 7:3 to 
1:1 gradient) 34 (65 mg, 0.23 mmol, 62%) as a yellow oil, mixture of stereoisomers 
(major/minor = 10.9:1  by 1H NMR). Analytical data from the 10.9:1 mixture of 
stereoisomers: 1H NMR (DMSO-d6) (major isomer) δ 8.58 (s, 1H), 8.30 (d, J = 8.0 Hz, 1H), 7.61 
64 
 
(d, J = 7.9 Hz, 1H), 7.21 (q, J = 7.2 Hz, 1H), 3.94 (s, 3H), 3.62 (s, 3H), 1.71 (d, J = 7.2 Hz, 3H); 1H 
NMR (DMSO-d6) (minor isomer) δ 8.49 (s, 1H), 8.27 (d, J = 7.4 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 
6.66 (q, J = 7.4 Hz, 1H), 3.56 (s, 3H), 2.24 (d, J = 7.3 Hz, 3H); 13C NMR (DMSO-d6) (major 
isomer) δ 164.8, 164.3, 148.2, 141.4, 134.3, 133.8, 133.7, 130.7, 130.5, 125.1, 52.9, 52.1, 15.5; 
13C NMR (DMSO-d6) (minor isomer, partial data) δ 149.6, 132.2, 123.9; IR (ATR) 2954, 1726, 
1534, 1436, 1350, 1280, 1198, 1114 cm-1; HRMS (ESI) calculated for C13H14NO6 (M+H+) 
280.0972; found, 280.0829. 
Methyl 1-hydroxy-5-methoxyindole-3-carboxylate (35). Treatment 
of 30 (89 mg, 0.36 mmol) in PhMe (5 mL) with sodium tert-pentoxide (40% solution in PhMe, 
250 μL, 0.83 mmol), as described for 19 (ambient temperature, 3 h), gave after 
chromatography (hexane/EtOAc 7:3) 35 (28 mg, 0.13 mmol, 36%) as an orange oil. 1H NMR 
(DMSO-d6) δ 10.90 (s, br, 1H), 6.95 (s, 1H), 6.34 (d, J = 2.3 Hz, 1H), 6.26 (d, J = 8.9 Hz, 1H), 
5.78 (dd, J = 8.9, 2.4 Hz, 1H), 2.65 (s, 3H), 2.65 (s, 3H); 13C NMR (DMSO-d6) δ 164.6, 155.6, 
130.4, 128.8, 123.3, 113.2, 110.6, 102.0, 100.1, 55.5, 50.9; IR (ATR) 3213, 2951, 1657, 
1435,1367, 1264, 1209, 1088, 1012 cm-1; HRMS (ESI) calculated for C11H12NO4 (M+H+) 
222.0761; found, 222.0771. 
Methyl 1,5-dimethoxyindole-3-carboxylate (36).  Treatment of 30 
(28 mg, 0.11 mmol) in PhMe (5 mL) with sodium tert-pentoxide (40% solution in PhMe, 28 
μL, 0.25 mmol) followed by dimethyl sulfate (32 μL, 0.34 mmol), as described for 12 
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(ambient temperature, 3 h) gave after chromatography (hexane/EtOAc 7:3) 36 (16 mg, 0.07 
mmol, 60%) as an orange oil. 1H NMR δ 7.89 (s, 1H), 7.65 (d, J = 2.4 Hz, 1H), 7.35 (d, J = 8.9 
Hz, 1H), 6.96 (dd, J = 8.9, 2.4 Hz, 1H), 4.13 (s, 3H), 3.90 (s, 3H), 3.89 (s, 3H); 13C NMR δ 165.3, 
156.5, 128.3, 127.2, 123.9, 114.4, 109.7, 103.0, 102.8, 66.9, 56.0, 51.2; IR (ATR) 2942, 1699, 
1518, 1456, 1369, 1262, 1201, 1086, 1016; HRMS (ESI) calculated for C12H14NO4 (M+H+) 
236.0917; found, 236.0929. 
Methyl 1-hydroxy-6-methoxyindole-3-carboxylate (37).  
Treatment of 31 (44 mg, 0.18 mmol) in PhMe (3 mL) with sodium tert-pentoxide (40% 
solution in PhMe, 121 μL, 0.41 mmol), as described for 19 (ambient temperature, 3 h), gave 
after chromatography (hexane/EtOAc 1:1) 37 (16 mg, 0.07 mmol, 42%) as an orange solid. 
mp = 137-140 °C; 1H NMR δ 9.13 (s, br, 1H), 7.81 (d, J = 8.7 Hz, 1H), 7.59 (s, 1H), 6.94-6.76 
(m, 2H), 3.81 (s, 3H), 3.80 (s, 3H); 13C NMR (CDCl3, DMSO-d6) δ 163.7, 155.6, 133.3, 128.0, 
120.6, 115.5, 111.1, 100.2, 90.5, 54.2, 49.6; IR (ATR) 3118, 1651, 1503, 1435, 1233, 1082 cm-
1; HRMS (ESI) calculated for C11H12NO4 (M+H+) 222.0761; found, 222.0772. 
Methyl 1,6-dimethoxyindole-3-carboxylate (38).  Treatment of 31 
(56 mg, 0.22 mmol) in PhMe (3 mL) with sodium tert-pentoxide (40% solution in PhMe, 154 
μL, 0.51 mmol) followed by dimethyl sulfate (63 μL, 0.66 mmol), as described for 12 
(ambient temperature, 3 h), gave after chromatography (hexane/EtOAc 7:3) 38 as an 
inseparable mixture with an unknown impurity. Alternative synthesis of 38. To a solution 
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of 37 (16 mg, 0.07 mmol) in acetone (3 mL) was added K2CO3 (19 mg, 0.14 mmol). The 
resulting suspension was stirred at ambient temperature for 10 min., then MeI (6 μL, 0.10 
mmol) was added and solution stirred for an additional 4 h at ambient temperature. Water 
was added to the reaction mixture followed by extraction with EtOAc (3 x 10mL). The 
combined organic phases were dried (MgSO4) and solvent was removed under reduced 
pressure. The resulting residue was purified by chromatography (hexane/EtOAc 7:3) to 
afford pure 38 (16 mg, 0.07 mmol, 94%) as a pale yellow oil that solidified upon standing. 
mp = 69-70 °C; 1H NMR δ 8.02 (dd, J = 8.7, 0.6 Hz, 1H), 7.86 (s, 1H), 6.94-6.89 (m, 2H), 4.13 
(s, 3H), 3.90 (s, 3H), 3.89 (s, 3H); 13C NMR δ 165.2, 157.6, 133.0, 127.4, 122.8, 117.0, 112.7, 
103.7, 91.7, 66.6, 55.8, 51.3; IR (ATR) 2945, 1699, 1521, 1440, 1230, 1078, 1016; HRMS (ESI) 
calculated for C12H14NO4 (M+H+) 236.0917; found, 236.0928. 
Methyl 5-carbomethoxy-1-hydroxyindole-3-carboxylate (39). 
Treatment of 33 (115 mg, 0.41 mmol) in PhMe (5 mL) with sodium tert-pentoxide (40% 
solution in PhMe, 285 μL, 0.94 mmol), as described for 19 (ambient temperature, 3 h), gave 
after chromatography (hexane/EtOAc 1:1) 39 (30 mg, 0.12 mmol, 29%) as a pale orange 
solid. mp = 148-150 °C; 1H NMR δ 11.34 (s br, 1H), 8.86 (s, 1H), 8.01-7.95 (m, 2H), 7.54 (d, J 
= 8.7 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H); 13C NMR (CDCl3, DMSO-d6) δ 167.4, 164.4, 135.6, 
131.4, 123.7, 123.6, 123.3, 121.5, 108.6, 102.8, 51.5, 50.7; IR (ATR) 3390, 2953, 1704, 1281, 
992, 763 cm-1; HRMS (ESI) calculated for C12H12NO5 (M+H+) 250.0710; found, 250.1198. 
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Methyl 5-carbomethoxy-1-methoxyindole-3-carboxylate (40).  
Treatment of 33 (65 mg, 0.23 mmol) in PhMe (5 mL) with sodium tert-pentoxide (40% 
solution in PhMe, 160 μL, 0.53 mmol) followed by dimethyl sulfate (66 μL, 0.69 mmol) as 
described for 12 (ambient temperature, 3 h) gave after chromatography (hexane/EtOAc 7:3) 
40 as an inseparable mixture with an unknown impurity. Alternative synthesis of 40. To a 
solution of 39 (11 mg, 0.04 mmol) in acetone (3 mL) was added K2CO3 (12 mg, 0.09 mmol). 
The resulting suspension was stirred at ambient temperature for 10 min., then MeI (4 μL, 
0.07 mmol) was added and the solution stirred for an additional 4 h at ambient temperature. 
The resultant mixture was quenched with H2O and extracted with EtOAc (3 x 10 mL). The 
combined organic phases were dried (MgSO4) and solvent was removed under reduced 
pressure. The residue was purified by chromatography (hexane/EtOAc 7:3) to afford pure 
40 (11 mg, 0.04 mmol, 93%) as a pale yellow oil that solidified upon standing. mp = 128-130 
°C; 1H NMR δ 8.89 (dd, J = 1.5, 0.6 Hz, 1H), 8.05-8.02 (m, 2H), 7.50 (dd, J = 8.7, 0.6 Hz, 1H), 
4.17 (s, 3H), 3.96 (s, 3H), 3.95 (s, 3H); 13C NMR δ 167.8, 164.7, 134.4, 130.0, 125.0, 124.8, 
124.7, 122.2, 108.6, 105.1, 67.1, 52.3, 51.6; IR (ATR) 2949, 1708, 1434, 1367, 1277, 1202, 
1081, 1023 cm-1; HRMS (ESI) calculated for C13H14NO5 (M+H+) 264.0866; found, 264.0880. 
Methyl 6-carbomethoxy-1-hydroxyindole-3-carboxylate (41).  
Treatment of 34 (110 mg, 0.40 mmol) in PhMe (5 mL) with sodium tert-pentoxide (40% 
solution in PhMe, 277 μL, 0.92 mmol) as described for 19 (ambient temperature, 3 h) gave 
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after chromatography (hexane/EtOAc 1:1) 41 (24 mg, 0.10 mmol, 25%) as a pale orange 
solid. mp = 156-157 °C; 1H NMR (DMSO-d6) δ 12.31 (s, br, 1H), 8.40 (s, 1H), 8.11-8.08 (m, 
2H), 7.82 (d, J = 8.3 Hz, 1H), 3.88 (s, 3H), 3.82 (s, 3H); 13C NMR (DMSO-d6) δ 166.5, 163.8, 
133.5, 132.9, 125.6, 123.9, 122.2, 120.6, 111.2, 101.3, 52.1, 51.0; IR (ATR) 3394, 1697, 1256, 
1211, 1023, 993, 762 cm-1; HRMS (ESI) calculated for C12H12NO5 (M+H+) 250.0710; found, 
250.1198. 
Methyl 6-carbomethoxy-1-methoxyindole-3-carboxylate (42).  
Treatment of 34 (41 mg, 0.15 mmol) in PhMe (3 mL) with sodium tert-pentoxide (40% 
solution in PhMe, 101 μL, 0.35 mmol) followed by dimethyl sulfate (42 μL, 0.45 mmol) as 
described for 12 (ambient temperature, 3 h) gave after chromatography (hexane/EtOAc 7:3) 
a 14.3:1 inseparable mixture of 42/34 (11.7:1 by 1H NMR) (17 mg, 0.07 mmol, 44%, 
calculated from spectrum) as an orange oil. 1H NMR δ 8.23-8.19 (m, 2H), 8.09 (s, 1H), 7.96 
(dd, J = 8.4, 1.5 Hz, 1H), 4.20 (s, 3H), 3.97 (s, 3H), 3.93 (s, 3H); 13C NMR δ 167.5, 164.7, 131.7, 
131.1, 126.3, 125.6, 123.5, 121.7, 11.2, 104.1, 67.4, 52.4, 51.5; IR (ATR) 2950, 1707, 1437, 
1381, 1254, 1206, 1070, 776 cm-1; HRMS (ESI) calculated for C13H14NO5 (M+H+) 264.0866; 
found, 264.0880. 
6-Amino-7-bromo-2,3-dihydro-5-methylinden-1-one (75). 2,3,5,6-
Tetrabromo-4-methyl-4-nitrocyclohexa-2,5-dienone 74 (2.13 g, 4.55 mmol) was added to a 
stirred solution of 68 (733 mg, 4.55 mmol) in AcOH (5 mL). The resulting solution was 
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stirred for 4 hours at ambient temperature and then poured into a 10% NaHCO3 (aq) solution 
(15 mL). The suspension was extracted with CH2Cl2 (3 x 30 mL) and the combined organics 
were washed with H2O (2 x 30 mL), dried (MgSO4), filtered, and concentrated in vacuo. The 
resulting residue was purified by flash chromatography (hexanes:EtOAc 8:2) to afford 75 
(640 mg, 2.66 mmol, 59%) as a brown solid. mp=177-179 °C; 1H NMR (600 MHz, CDCl3) δ 
2.30 (s, 3H), 2.67-2.72 (m, 2H), 2.93-2.97 (m, 2H), 4.26 (br s, 2H), 7.11 (s, 1H); 13C NMR (151 
MHz, CDCl3) δ 19.2, 23.8, 37.4, 103.6, 126.7, 131.2, 132.5, 142.4, 147.4, 204.2; IR (ATR) 871, 
1318, 1469, 1621, 1688, 3352, 3378 cm-1; HRMS (ESI) calculated for C10H11BrNO (M+H+) 
240.0024, found 240.0018. 
N-(2,3-Dihydro-5-methyl-1-oxo-1H-inden-6-yl)acetamide (69). To a 
stirring solution of 68 (4.62 g, 28.7 mmol) in 100 mL of CH2Cl2 was added NEt3 (3.19 g, 31.5 
mmol) at ambient temperature and the solution was allowed to stir for 15 min. Acetyl 
chloride (2.70 g, 34.4 mmol) was then added dropwise and the reaction mixture was stirred 
for 22 h at ambient temperature. The crude mixture was washed with water (2 x 100 mL) 
and brine (1 x 100 mL), dried (MgSO4), filtered, and concentrated in vacuo. The residue was 
purified by flash chromatography (EtOAc) to give 69 (4.86 g, 23.9 mmol, 84%) as a tan solid. 
mp = 221-223 °C; 1H NMR (600 MHz, CDCl3) δ 2.21 (s, 3H), 2.34 (s, 3H), 2.66-2.68 (m, 2H), 
3.05-3.07 (m, 2H), 7.14 (br s, 1H), 7.31 (s, 1H), 7.95 (s, 1H); 13C NMR (151 MHz, CDCl3) δ 18.9, 
24.0, 25.3, 36.6, 119.2, 128.4, 135.2, 136.0, 138.8, 152.4, 168.5, 206.0; IR (ATR) 864, 1527, 
1656, 1691, 3310 cm-1; HRMS (ESI) calculated for C12H14NO2 (M+H+) 204.1019, found 
204.1019. 
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N-(2,3-Dihydro-5-methyl-7-nitro-1-oxo-1H-inden-6-yl)acetamide (70). 
Fuming nitric acid (10 mL) was stirred at -20 °C for 5 min, then 25 drops of concentrated 
H2SO4 was added and the resulting mixture was stirred at -20 °C for 20 min. This mixture 
was added dropwise to 69 (1.0 g, 4.92 mmol), cooled to -20 °C, and stirred at the same 
temperature for 1.5 h before quenching with 20 mL of H2O and then 20 mL of a saturated 
NH4Cl solution (aq). The aqueous mixture was extracted with EtOAc (3 x 50 mL) and washed 
with H2O (3 x 50 mL). The organic phase was dried (MgSO4), filtered, and concentrated in 
vacuo. The resulting residue was purified by flash chromatography (EtOAc) to afford 70 (860 
mg, 3.46 mmol, 70%) as a dark yellow solid. mp = 225-227 °C; 1H NMR δ 2.18 (s, 3H), 2.39 
(s, 3H), 2.77-2.79 (m, 2H), 3.14-3.16 (m, 2H), 7.31 (br s, 1H), 7.53 (s, 1H); 13C NMR  δ 19.5, 
23.2, 25.3, 36.8, 126.1, 126.7, 130.7, 142.4, 146.3, 154.6, 168.9, 200.4; IR (ATR) 782, 1536, 
1673, 1718, 3347 cm-1; HRMS (ESI) calculated for C12H13N2O4 (M+H+) 249.0870, found 
249.0871. 
6-Amino-2,3-dihydro-5-methyl-7-nitroinden-1-one (71). A solution of 70 
(140 mg, 0.56 mmol) in EtOH (15 mL) was refluxed with 5 M HCl (aqueous, 10 mL) for 18 h. 
The organic phase was removed in vacuo and the resulting aqueous solution was made 
alkaline (pH 8-9) with a NaOH solution (aq). This solution was then extracted with CH2Cl2 (3 
x 20 mL), dried (MgSO4), filtered, and concentrated in vacuo. The resulting residue was 
71 
 
purified by flash chromatography (hexanes:EtOAc 1:1) to afford 71 (98 mg, 0.48 mmol, 84%) 
as a bright yellow solid. mp = 229-231 °C; 1H NMR (600 MHz, CDCl3) δ 2.32 (s, 3H), 2.72-2.74 
(m, 2H), 2.97-2.99 (m, 2H), 5.10 (br s, 2H), 7.31 (s, 1H); 13C NMR (151 MHz, CDCl3) δ 18.6, 
24.6, 37.1, 129.0, 131.2, 133.6, 139.7, 145.7, 200.6 (1 resonance not found); IR (ATR) 887, 
1313, 1518, 1634, 1689, 3362, 3460 cm-1; HRMS (ESI) calculated for C10H11N2O3 (M+H+) 
207.0764, found 207.0764. 
2,3-Dihydro-6-iodo-5-methyl-7-nitroinden-1-one (72). To a stirred 
solution of 71 (21 mg, 0.10 mmol) in concentrated HCl (1 mL) and ice at 0 °C, a solution of 
sodium nitrite (8 mg, 0.11 mmol) in H2O (1 mL) was added dropwise. The mixture was 
stirred at 0 °C for 30 min before adding it dropwise to a stirred solution of KI (50 mg, 0.30 
mmol) in H2O (1 mL) at ambient temperature. The mixture remained stirring for 16 hours at 
ambient temperature and was then extracted with CH2Cl2 (3 x 20 mL). The combined organic 
extracts were washed with 10% NaOH (aq.) (1 x 20 mL), 5% NaHCO3 (aq.) (1 x 20 mL), and 
H2O (1 x 20 mL) before being dried (MgSO4), filtered, and concentrated in vacuo. The 
resulting dark yellow residue was purified by flash chromatography (hexanes: EtOAc, 9:1 
then 8:2) to afford 72 (20 mg, 0.063 mmol, 63%) as an off-white solid. mp = 173-175 °C; 1H 
NMR δ 2.60 (s, 3H), 2.73-2.75 (m, 2H), 2.98-3.00 (m, 2H), 7.28 (s, 1H); 13C NMR δ 24.5, 31.1, 
36.9, 107.4, 125.8, 131.8, 136.3, 150.5, 156.8, 201.9; IR (ATR) 871, 1149, 1432, 1694, 2923 
cm-1; HRMS (ESI) calculated for C10H9INO3 (M+H+) 317.9627 (peak not found 
experimentally). 
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6-Bromo-2,3-dihydro-5-methylinden-1-one (76).  
Method 1 (Table 5, entry 1): A solution of 68 (100 mg, 0.62 mmol) in HBr (48%, 500 μL), H2O 
(1 mL), and 1,4-dioxane (500 μL) was heated to reflux for 20 min. The resulting solution was 
cooled to ambient temperature, then placed in an ice bath. A solution of NaNO2 (40 mg, 0.62 
mmol) in H2O (1 mL) was added dropwise, and the resulting orange solution stirred at 0 °C 
for 20 min. This solution was added dropwise to a solution of CuBr (100 mg, 0.68 mmol) in 
HBr (48%, 500 μL) and H2O (1 mL) at 0 °C, during which time the evolution of gas was 
observed. The dark red-brown solution was warmed to ambient temperature and stirred for 
16 h. The solution was quenched by slow addition of saturated NaHCO3 (aq) and extracted 
with EtOAc (3 x 10 mL). The combined organics were washed with H2O (10 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. The resulting residue was purified by flash 
chromatography (hexanes:EtOAc 8:2) to afford 76 (104 mg, 0.46 mmol, 75%) as an orange 
solid. 
Method 2 (Table 5, entry 3): 67 (2.0 g, 13.7 mmol) was added to stirring conc. H2SO4 (15 mL) 
at ambient temperature. N-bromosuccinimide (NBS, 3.05 g, 17.1 mmol) was added in 
portions, and the resulting orange solution stirred at ambient temperature for 3 h. The 
reaction was quenched by addition of ice chips and the solution was extracted with EtOAc (3 
x 15 mL). The combined organics were washed with saturated NaHCO3 (aq, 15 mL) and brine 
(15 mL), dried (MgSO4), filtered, and concentrated in vacuo. The resulting residue was 
purified by flash chromatography (hexanes: EtOAc, 9:1 to 7:3 gradient) to afford 76 (973 mg, 
4.33 mmol, 32%) as an orange solid, and 77 (1.26 g, 5.61 mmol, 41%) as a pale orange solid.  
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Analytical data for 76: mp = 114-116 oC; 1H NMR (600 MHz, CDCl3) δ 7.92 (s, 1H), 7.36 (s, 
1H), 3.07-3.04 (m, 2H), 2.71-2.68 (m, 2H), 2.48 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 205.1, 
154.0, 144.9, 136.7, 128.6, 127.4, 124.4, 36.5, 25.3, 23.9; IR (ATR) 1702, 1597, 1432, 1379, 
1171, 884 cm-1; HRMS (ESI) calculated for C10H10BrO (M+H+) 224.9915, found 224.9918. 
 4-Bromo-2,3-dihydro-5-methylinden-1-one (77). 
Method 1 (Table 5, entry 2): 67 (500 mg, 3.42 mmol) in CH2Cl2 (4 mL) was added dropwise 
over 30 min to a suspension of AlCl3 (910 mg, 6.84 mmol) in CH2Cl2 (4 mL). To this solution 
was added Br2 (190 μL, 3.76 mmol) in CH2Cl2 (4 mL) dropwise. The resulting dark red-
orange solution was heated to 50 C and stirred for 22 h. The solution was cooled to ambient 
temperature and quenched by slow addition of H2O (5 mL). The organics were washed with 
H2O (10 mL) and brine (10 mL), dried (MgSO4), filtered, and concentrated in vacuo. The 
resulting residue was purified by flash chromatography (hexanes:EtOAc 9:1) to afford 77 
(92 mg, 0.41 mmol, 12%) as a pale orange solid.  
Method 2 (Table 5, entry 3): 67 (2.0 g, 13.7 mmol) was added to stirring conc. H2SO4 (15 mL) 
at ambient temperature. N-bromosuccinimide (NBS, 3.05 g, 17.1 mmol) was added in 
portions, and the resulting orange solution stirred at ambient temperature for 3 h. The 
reaction was quenched by addition of ice chips and the solution was extracted with EtOAc (3 
x 15 mL). The combined organics were washed with saturated NaHCO3 (aq, 15 mL) and brine 
(15 mL), dried (MgSO4), filtered, and concentrated in vacuo. The resulting residue was 
purified by flash chromatography (hexanes: EtOAc, 9:1 to 7:3 gradient) to afford 76 (973 mg, 
4.33 mmol, 32%) as an orange solid, and 77 (1.26 g, 5.61 mmol, 41%) as a pale orange solid.  
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Analytical data for 77: mp = 65-68 oC; 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 7.7 Hz, 1H), 
7.27 (d, J = 9.7 Hz, 1H), 3.09-3.05 (m, 2H), 2.75-2.72 (m, 2H), 2.51 (s, 3H); 13C NMR (151 MHz, 
CDCl3) δ 205.8, 155.4, 145.1, 136.8, 130.2, 124.1, 122.0, 36.4, 27.5, 23.1; IR (ATR) 1702, 1595, 
1258, 1116, 1038, 808 cm-1; HRMS (ESI) calculated for C10H10BrO (M+H+) 224.9915, found 
224.9917. 
6-Bromo-2,3-dihydro-5-methyl-4-nitroinden-1-one (78). 76 (1.52 g, 
6.77 mmol) was reacted with fuming HNO3 (15 mL) and conc. H2SO4 (40 drops) as described 
for 70 (-20 °C, 90 min). After chromatography (hexanes:EtOAc 7:3 then EtOAc), 78 (317 mg, 
1.18 mmol, 17%, off-white solid) and 79 (1.15 g, 4.30 mmol, 64%, orange solid) were 
obtained. Analytical data for 78: mp = 145 °C (sublimation); 1H NMR (600 MHz, chloroform-
d) δ 8.11 (s, 1H), 3.20-3.16 (m, 2H), 2.80-2.76 (m, 2H), 2.56 (s, 3H); 13C NMR (151 MHz, 
chloroform-d) δ 202.6, 147.0, 145.8, 137.8, 137.3, 130.2, 126.2, 35.9, 23.9, 19.6; IR (ATR) 
3069, 1712, 1527, 1356, 1241, 1199, 1161 cm-1; HRMS (ESI) calculated for C10H9BrNO3 
(M+H+) 271.97, found 271.9748. 
6-Bromo-2,3-dihydro-5-methyl-7-nitroinden-1-one (79). 76 (1.52 g, 6.77 
mmol) was reacted with fuming HNO3 (15 mL) and conc. H2SO4 (40 drops) as described for 
70 (-20 °C, 90 min). After chromatography (hexanes:EtOAc 7:3 then EtOAc), 78 (317 mg, 
1.18 mmol, 17%, off-white solid) and 79 (1.15 g, 4.30 mmol, 64%, orange solid) were 
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obtained. Analytical data for 79: mp = 137-138 °C; 1H NMR (600 MHz, chloroform-d) δ 7.51 
(s, 1H), 3.14-3.11 (m, 2H), 2.80-2.78 (m, 2H), 2.57 (s, 3H); 13C NMR (151 MHz, chloroform-d) 
δ 199.7, 154.7, 147.0, 145.4, 129.7, 126.3, 114.1, 36.3, 25.0, 23.9; IR (ATR) 2928, 1704, 1599, 
1538, 1431, 1375, 1309, 1165, 887, 801 cm-1; HRMS (ESI) calculated for C10H9BrNO3 (M+H+) 
271.97, found 271.9745. 
6-(3-hydroxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1-
one (64). To an oven-dried flask equipped with a cold water condenser were added 79 (688 
mg, 2.56 mmol), PdCl2(PPh3)2 (36 mg, 0.05 mmol), and PPh3 (27 mg, 0.10 mmol), and the 
system was purged with N2. 1,4-dioxane (anhydrous, 15 mL) was added via syringe, and the 
solution was stirred at ambient temperature. (E)-3-(tributylstannyl)-2-propen-1-ol (65, 
1.15 g, 3.33 mmol) in 1,4-dioxane (anhydrous, 5 mL) was added via syringe and the solution 
was heated to 110 °C for 120 h. The resulting reaction mixture was cooled to ambient 
temperature and quenched with H2O (20 mL). Solution was extracted with EtOAc (3 x 30 
mL). The combined organics were washed with brine (3 x 30 mL), dried (MgSO4), filtered, 
and concentrated in vacuo. The resulting residue was purified by flash chromatography 
(hexanes:EtOAc 2:8) to afford 64 (345 mg, 1.40 mmol, 55%) as a pale yellow oil. 1H NMR 
(600 MHz, chloroform-d) δ 7.43 (s, 1H), 6.51 (d, J = 16.2 Hz, 1H), 6.06 (dt, J = 16.2, 4.6 Hz, 
1H), 4.30 (dd, J = 4.6, 1.9 Hz, 2H), 3.15-3.11 (m, 2H), 2.76-2.72 (m, 2H), 2.42 (s, 3H), 2.18 (s, 
br, 1H); 13C NMR (151 MHz, chloroform-d) δ 201.2, 154.8, 146.4, 144.0, 137.3, 129.3, 128.1, 
125.1, 120.5, 62.7, 36.5, 25.2, 21.3; IR (ATR) 3409, 2924, 1710, 1614, 1536, 1381, 1314, 1124, 
1022 cm-1; HRMS (ESI) calculated for C13H14NO4 (M+H+) 248.09, found 248.0928. 
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6-(3-methoxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1-
one (81). To an oven-dried flask equipped with a cold water condenser were added 79 (601 
mg, 2.23 mmol), PdCl2(PPh3)2 (32 mg, 0.05 mmol), and PPh3 (24 mg, 0.09 mmol), and the 
system was purged with N2. 1,4-dioxane (anhydrous, 15 mL) was added via syringe, and the 
solution was stirred at ambient temperature. (E)-tributyl(3-methoxy-1-propenyl)stannane 
(80, 1.05 g, 2.90 mmol) in 1,4-dioxane (anhydrous, 7 mL) was added via syringe and the 
solution was heated to 110 °C for 120 h. The resulting reaction mixture was cooled to 
ambient temperature and quenched with H2O (20 mL). Solution was extracted with EtOAc 
(3 x 30 mL). The combined organics were washed with brine (3 x 30 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. The resulting residue was purified by flash 
chromatography (hexanes:EtOAc 1:1) to afford 81 (467 mg, 1.79 mmol, 80%) as an orange 
solid. mp = 109-113 °C; 1H NMR (400 MHz, chloroform-d) δ 7.43 (s, 1H), 6.49 (d, J = 16.2 Hz, 
1H), 5.99 (dt, J = 16.2, 5.0 Hz, 1H), 4.05 (dd, J = 5.0, 1.8 Hz, 2H), 3.39 (s, 3H), 3.16-3.10 (m, 
2H), 2.78-2.73 (m, 2H), 2.43 (s, 3H); 13C NMR (151 MHz, chloroform-d) δ 200.9, 154.8, 146.2, 
134.9, 131.9, 129.3, 128.2, 125.2, 122.0, 72.2, 58.3, 36.5, 25.2, 21.4; IR (ATR) 2929, 1716, 
1615, 1539, 1441, 1382, 1315, 1186, 1120 cm-1; HRMS (ESI) calculated for C14H16NO4 (M+H+) 
262.1074, found 262.1084. 
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3-methoxy-5-(3-methoxy-1-propenyl)-6-methyl-4-nitroindene 
(83). 81 (101 mg, 0.39 mmol) was dissolved in MeOH (3 mL), and p-toluenesulfonic acid (3 
mg, 0.02 mmol) was added, followed by trimethyl orthoformate (84 μL, 0.77 mmol). The 
resulting solution was stirred at ambient temperature for 16 h before being diluted with 
EtOAc (5 mL) and quenched with a solution of NaOH (1M, 5 mL).  This solution was extracted 
with EtOAc (3 x 10 mL), and the combined organics were dried (MgSO4), filtered, and 
concentrated in vacuo. The resulting residue was purified by flash chromatography 
(hexanes:EtOAc 7:3 to 1:1 gradient) to afford 83 (13 mg, 0.05 mmol, 12%) as a viscous 
yellow oil and unreacted 81 (11 mg, 0.04 mmol, 11%). Analytical data for 83: 1H NMR (600 
MHz, chloroform-d) δ 7.30 (s, 1H), 6.53 (d, J = 16.3 Hz, 1H), 5.94 (dt, J = 16.2, 5.4 Hz, 1H), 5.35 
(t, J = 2.4 Hz, 1H), 4.07-4.05 (m, 2H), 3.79 (s, 3H), 3.38 (s, 3H), 3.30 (d, J = 2.3 Hz, 2H), 2.36 (s, 
3H); 13C NMR (151 MHz, chloroform-d) δ 156.2, 143.8, 135.0, 133.3, 128.0, 126.9, 126.8, 
126.5, 124.2, 100.0, 72.6, 58.0, 57.3, 33.6, 20.6; IR (ATR) 2927, 1712, 1613, 1533, 1379, 1116 
cm-1; HRMS (ESI) calculated for C13H14NO4 (M+H+) 276.12, found 276.1232. 
6-(1,2-epoxy-3-hydroxypropyl)-2,3-dihydro-5-methyl-7-
nitroinden-1-one (89). 64 (340 mg, 1.40 mmol) was dissolved in CH2Cl2 (10 mL), and 
solution was cooled to 0 °C. 3-chloroperoxybenzoic acid (m-CPBA, 70-75%/wt, 1.38 g, 5.60 
mmol) was added in portions. The resulting suspension was warmed to ambient 
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temperature and stirred for 16 h. The reaction mixture was quenched by slow addition of 
saturated Na2SO3 (aq, 10 mL) and diluted with CH2Cl2 (5 mL), then washed with saturated 
NaHCO3 (aq, 10 mL) and brine (10 mL). The organics were dried (Na2SO4), filtered, and 
concentrated in vacuo. The resulting residue was purified by flash chromatography (EtOAc) 
to afford 89 (268 mg, 1.02 mmol, 74%) as a colorless oil. 1H NMR (600 MHz, chloroform-d) 
δ 7.46 (s, 1H), 4.07 (d, J = 2.3 Hz, 1H), 3.99 (dd, J = 13.0, 2.6 Hz, 1H), 3.82 (dd, J = 13.0, 3.1 Hz, 
1H), 3.15-3.12 (m, 3H), 2.75-2.72 (m, 2H), 2.55 (s, 3H), 2.36 (s, br, 1H); 13C NMR (151 MHz, 
chloroform-d) δ; IR (ATR) 3419, 2927, 1713, 1618, 1541, 1372, 1309, 1121, 903 cm-1; HRMS 
(ESI) calculated for C13H14NO5 (M+H+) 264.0866, found 264.0876. 
6,7-dihydro-2-(hydroxymethyl)-4-methylcyclopent[g]-(N-
hydroxy)indol-8(1H)-one (90). Method from Table 6, entry 2: To a thick-walled pressure 
tube was added 89 (84 mg, 0.32 mmol) and Pd/C (10% Pd, 7 mg, 0.006 mmol). Absolute 
EtOH (3 mL) was added, and the resulting suspension was charged with 40 psi H2. The 
reaction mixture was heated to 50 °C and stirred for 12 h. The solution was cooled to ambient 
temperature and filtered over Celite, rinsing with hot EtOH, and the filtrate was concentrated 
in vacuo. The resulting residue was purified by flash chromatography (hexanes:EtOAc 1:1) 
to afford 90 (27 mg, 0.12 mmol, 37%) as a yellow solid. mp = 164-166 °C; 1H NMR (400 MHz, 
DMSO-d6/chloroform-d) δ 11.69 (s, br, 1H), 6.87 (s, 1H), 6.39 (s, 1H), 4.98 (t, J = 5.8 Hz, 1H), 
4.73 (d, J = 5.6 Hz, 2H), 3.26-3.22 (m, 2H), 2.77-2.73 (m, 2H), 2.55 (s, 3H); 1H NMR (400 MHz, 
chloroform-d) δ 12.17 (s, 1H), 6.88 (s, 1H), 6.39 (s, 1H), 4.86 (d, J = 6.6 Hz, 2H), 3.31-3.27 (m, 
2H), 2.84-2.79 (m, 2H), 2.57 (s, 3H), 2.23 (t, J = 6.6 Hz, 1H); 13C NMR (101 MHz, DMSO-
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d6/chloroform-d) δ 206.8, 153.0, 140.4, 135.3, 125.6, 121.1, 118.4, 116.6, 95.2, 54.3, 35.5, 
26.9, 18.7; IR (ATR) 3350, 2925, 1614, 1367, 1299, 1158, 1076, 1006 cm-1; HRMS (ESI) 
calculated for C13H14NO3 (M+H+) 232.0968, found 232.0978. 
6,7-dihydro-2,4-dimethylcyclopent[g]indol-8(1H)-one (91). Method 
from Table 6, entry 3: To a thick-walled pressure tube was added 89 (58 mg, 0.22 mmol) and 
Pd/C (10% Pd, 12 mg, 0.011 mmol). Absolute EtOH (3 mL) was added, and the resulting 
suspension was charged with 40 psi H2. The reaction mixture was heated to 50 °C and stirred 
for 16 h. The solution was cooled to ambient temperature and filtered over Celite, rinsing 
with hot EtOH, and the filtrate was concentrated in vacuo. The resulting residue was purified 
by flash chromatography (hexanes:EtOAc 1:1) to afford 91 as a pale-orange viscous oil. 1H 
NMR (400 MHz, chloroform-d) δ 9.19 (s, br, 1H), 6.93 (s, 1H), 6.27 (s, 1H), 3.23-3.16 (m, 2H), 
2.74-2.68 (m, 2H), 2.58 (s, 3H), 2.48 (s, 3H); 13C NMR (101 MHz, DMSO-d6/chloroform-d) δ 
206.7, 151.4, 138.7, 135.0, 130.3, 128.1, 119.2, 117.7, 99.0, 36.5, 26.6, 19.7, 13.6; IR (ATR) 
3327, 2921, 1678, 1633, 1554, 1298 cm-1; HRMS (ESI) calculated for C13H14NO (M+H+) 
200.1075, found 200.1070. 
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Dilemmaone B (53).  
Method A (Table 6, entry 4): 90 (17 mg, 0.074 mmol) was reacted with Pd/C (10% Pd, 4 mg, 
0.004 mmol) and EtOH (3mL) under 40 psi H2 as described for 91 (50 °C, 2 h) to afford after 
purification (hexanes:EtOAc 2:8) 53 (4 mg, 0.02 mmol, 27%) as an off-white solid.  
Method B (Table 6, entry 5): To a thick-walled pressure tube was added 89 (126 mg, 0.48 
mmol) and PtO2 (3 mg, 0.010 mmol). Absolute EtOH (3 mL) was added, and the resulting 
suspension was charged with 40 psi H2. The reaction mixture was heated to 50 °C and stirred 
for 3 h. The solution was cooled to ambient temperature and filtered over Celite, rinsing with 
hot EtOH, and the filtrate was concentrated in vacuo. The resulting residue was purified by 
flash chromatography (hexanes:EtOAc 2:8) to afford 53 (49 mg, 0.23 mmol, 48%) as an off-
white solid. 
Analytical data for 53: mp = 188-190 °C; 1H NMR (400 MHz, chloroform-d) δ 9.70, 6.97, 6.49, 
4.87, 3.21, 2.73, 2.60, 2.04 (multiplicity not reported as solubility in chloroform-d is poor—
full analysis was done in DMSO-d6); 1H NMR (600 MHz, DMSO-d6) δ 11.30 (s, br, 1H), 6.94 (s, 
1H), 6.43 (s, 1H), 5.07 (t, J = 6.1 Hz, 1H), 4.61 (d, J = 6.1 Hz, 2H), 3.15-3.11 (m, 2H), 2.65-2.60 
(m, 2H), 2.53 (s, 3H); 13C NMR (151 MHz, DMSO-d6) δ 204.7, 151.4, 140.7, 138.1, 129.4, 127.3, 
119.3, 117.2, 98.1, 56.6, 35.9, 26.0, 19.2; IR (ATR) 3376, 2851, 1634., 1556, 1439, 1299, 1233, 
1125, 1025 cm-1; HRMS (ESI) calculated for C13H14NO2 (M+H+) 216.1019, found 216.1028. 
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6-(1,2-epoxy-3-methoxypropyl)-2,3-dihydro-5-methyl-7-
nitroinden-1-one (92). 81 (220 mg, 0.84 mmol) was reacted with m-CPBA (70-75%/wt, 
830 mg, 3.36 mmol) in CH2Cl2 (5mL) as described for 89 to afford after purification 
(hexanes:EtOAc 2:8) 92 (119 mg, 0.43 mmol, 51%) as a colorless oil. 1H NMR (400 MHz, 
chloroform-d) δ 7.46 (s, 1H), 3.95 (d, J = 1.8 Hz, 1H), 3.77(dd, J = 11.7, 2.8 Hz, 1H), 3.54 (dd, J 
= 11.7, 4.8 Hz, 1H), 3.42 (s, 3H), 3.18-3.10 (m, 3H), 2.77-2.70 (m, 2H), 2.56 (s, 3H); 13C NMR 
(101 MHz, chloroform-d) δ 216.0, 200.5, 186.8, 155.9, 147.2, 130.0, 126.0, 125.2, 71.2, 59.4, 
57.7, 51.4, 36.5, 25.2, 20.2; IR (ATR) 2929, 1714, 1618, 1541, 1449, 1371, 1309, 1110, 907 
cm-1; HRMS (ESI) calculated for C14H16NO5 (M+H+) 278.1028, found 278.1025. 
Dilemmaone A (52).  
Method A (Scheme 19): 92 (88 mg, 0.32 mmol) was reacted with Pd/C (10% Pd, 7 mg, 0.006 
mmol) and EtOH (3mL) under 40 psi H2 as described for 90 (50 °C, 16 h) to afford after 
purification (hexanes:EtOAc 1:1) 52 (22 mg, 0.10 mmol, 30%) as an off-white solid. 
Method B (Scheme 19): 92 (119 mg, 0.43 mmol) was reacted with PtO2 (2 mg, 0.009 mmol) 
and EtOH (3mL) under 40 psi H2 as described for 53 (50 °C, 4 h) to afford after purification 
(hexanes:EtOAc 1:1) 52 (25 mg, 0.11 mmol, 25%) as an off-white solid. 
mp = 151-154 °C; 1H NMR (400 MHz, CDCl3) δ 9.52 (s, br, 1H), 6.95 (s, 1H), 6.49 (d, J = 2.2 Hz, 
1H), 4.61 (s, 2H), 3.37 (s, 3H), 3.22-3.17 (m, 2H), 2.73-2.69 (m, 2H), 2.59 (s, 3H).; 1H NMR 
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(600 MHz, DMSO-d6) δ 11.59 (s, br, 1H), 6.95 (s, 1H), 6.52 (d, J = 1.8 Hz, 1H), 4.54 (s, 2H), 3.28 
(s, 3H), 3.14-3.11 (m, 2H), 2.64-2.61 (m, 2H), 2.54 (s, 3H); 13C NMR (151 MHz, DMSO-d6) δ 
204.6, 152.0, 138.3, 136.2, 129.5, 127.3, 119.5, 117.3, 100.4, 66.4, 57.2, 35.9, 26.0, 19.2; IR 
(ATR) 3339, 2920, 1657, 1560, 1294, 1128 cm-1; HRMS (ESI) calculated for C14H16NO2 
(M+H+) 230.1181, found 230.1174. 
4-Amino-6-bromo-2,3-dihydro-5-methylinden-1-one (95). 78 (440 mg, 
1.63 mmol) was combined in a thick-walled glass pressure tube with Pd/C (10% Pd, 35 mg, 
0.03 mmol) and absolute EtOH (6 mL). The resulting suspension was charged with 40 psi H2 
and the system was heated to 50 °C and stirred for 21 h. The reaction mixture was cooled to 
ambient temperature and filtered over Celite, rinsing with hot EtOH. The combined filtrates 
were concentrated in vacuo, and without further purification 95 (391 mg, 1.29 mmol, 79%) 
was obtained as a tan solid. mp = 183-192 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.01 (s, 1H), 
5.56 (br, s, 2H), 2.78 (m, 2H), 2.64-2.60 (m, 2H), 2.26 (s, 3H); 13C NMR (100 MHz, DMSO-d6) 
δ 205.6, 145.4, 139.1, 136.1, 124.5, 123.6, 112.8, 35.9, 23.1, 17.6; IR (ATR) 3346, 2910, 1693, 
1632, 1587, 1429, 1294, 1094 cm-1; HRMS (ESI, negative mode) calculated for C10H9BrNO 
(M-H+) 239.9853, found 239.9847. 
6-Bromo-2,3-dihydro-4-hydroxy-5-methylinden-1-one (96). 95 (481 mg, 
2.01 mmol) was suspended in H2O (7 mL), and concentrated H2SO4 was added dropwise until 
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dissolution of the solid (approx.. 8 mL). This solution was heated to 45 °C and stirred for 30 
min. The solution was removed from heat and allowed to cool to ambient temperature before 
being placed in an ice bath. A solution of NaNO2 (420 mg, 6.04 mmol) in H2O (3 mL) was 
added dropwise, and the resulting solution stirred at 0 °C for 10 min before being heated to 
reflux and stirred for 16 h. The resulting mixture was cooled to ambient temperature and 
then added slowly in portions to a flask of ice water. Upon addition, a dark precipitate was 
immediately formed. The suspension was filtered rinsing with cold H2O, and the solid was 
dried in vacuo to afford 96 (185 mg, 0.77 mmol, 38%) as a brown solid without further 
purification. 1H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 7.31 (s, 1H), 2.96-2.92 (m, 2H), 2.65-
2.62 (m, 2H), 2.33 (s, 3H). 
6-Bromo-2,3-dihydro-4-hydroxy-5-methyl-7-nitroinden-1-one (97). 96 
(88 mg, 0.36 mmol) was reacted with fuming HNO3 (2 mL) and conc. H2SO4 (5 drops) as 
described for 70 (-20 °C, 90 min). After chromatography (hexanes:EtOAc 1:1), 97 (33 mg, 
0.12 mmol, 32%) was obtained as an orange solid. 1H NMR (400 MHz, chloroform-d) δ 2.92-
2.87 (m, 2H), 2.84-2.79 (m, 2H), 1.68 (s, 3H). 
3-(2-nitrophenyl)-3-buten-1-ol (106). To a round-bottomed flask 
equipped with cold-water condenser was added Pd(dba)2 (11 mg, 0.02 mmol), dppf (21 mg, 
0.04 mmol), and urotropine (104 mg, 0.74 mmol), and the system was purged with N2. DMA 
(3 mL) was added via syringe, and the solution was heated to 105 °C. A mixture of 3-buten-
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1-ol (63 μL, 0.74 mmol) and 105 (100 mg, 0.37 mmol) in DMA (2 mL) was added via syringe, 
and the solution stirred at 105 °C for 72 h. The resulting mixture was cooled to ambient 
temperature and quenched with H2O then extracted with EtOAc (3 x 10 mL). The combined 
organics were washed with saturated NaHCO3 (aq., 10 mL) and brine (10 mL), dried (MgSO4), 
and solvents were removed in vacuo. The resulting residue was purified by flash 
chromatography (hexanes:EtOAc 7:3 to 2:8) to afford 106 (34 mg, 0.18 mmol, 47%) as an 
orange oil as a mixture of stereoisomers (106/107 = 6.3:1 by 1H NMR), and 2-nitrophenol 
(6 mg, 0.04 mmol, 11%). Analytical data for the 6.3:1 mixture (data provided for compound 
106): 1H NMR (400 MHz, chloroform-d) δ 7.86 (d, J = 8.2 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.43 
(t, J = 7.8 Hz, 1H), 7.35 (d, J = 7.6 Hz, 1H), 5.30 (s, 1H), 5.08 (s, 1H), 3.72 (t, J = 5.8 Hz, 2H), 
2.70 (t, J = 6.0 Hz, 2H), 1.84 (br s, 1H).  
4-(2-nitrophenyl)-3-buten-1-ol (107). Method used to obtain 107 as 
the major isomer: To a round-bottomed flask equipped with cold-water condenser was 
added 105 (500 mg, 1.85 mmol), Pd(OAc)2 (20 mg, 0.09 mmol) and PPh3 (50 mg, 0.19 mmol), 
and the system was purged with N2. NEt3 (9.25 mL) was added via syringe, followed by 3-
buten-1-ol (320 μL, 3.7 mmol) via syringe. The solution was heated to 80 °C and stirred for 
18 h. The resulting reaction mixture was cooled to ambient temperature and quenched with 
H2O then extracted with EtOAc (3 x 10 mL). The combined organics were washed with 
saturated NaHCO3 (aq., 10 mL) and brine (10 mL), dried (MgSO4), and solvents were 
removed in vacuo. The resulting residue was purified by flash chromatography 
(hexanes:EtOAc 7:3 to 1:1) to afford 107 (22 mg, 0.11 mmol, 6%) as an orange oil as a 
mixture of stereoisomers (major/minor = 3.6:1 by 1H NMR). Analytical data for the 3.6:1 
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mixture: 1H NMR (400 MHz, chloroform-d, major isomer) δ 7.90 (dd, J = 8.2, 1.2 Hz, 1H), 7.56 
(dtd, J = 15.6, 8.1, 1.4 Hz, 2H), 7.41-7.33 (m, 2H), 6.95 (d, J = 15.7 Hz, 1H), 6.23 (dt, J = 15.7, 
7.1 Hz, 1H), 3.81 (t, J = 6.2 Hz, 2H), 2.55 (qd, J = 6.3, 1.4 Hz, 2H); 1H NMR (400 MHz, 
chloroform-d, minor isomer, partial data) δ 7.85 (dd, J = 8.1, 1.3 Hz, 1H), 7.43 (td, J = 7.8, 1.5 
Hz, 2H), 6.86 (d, J = 11.5 Hz, 1H). 
 3-(2-bromo-6-nitrophenyl)-3-buten-1-ol (110). 108 (520 mg, 1.49 
mmol) was reacted with 3-buten-1-ol (256 μL, 2.98 mmol), Pd(dba)2 (43 mg, 0.08 mmol), 
dppf (83 mg, 0.15 mmol), and urotropine (417 mg, 2.98 mmol) in DMA (7 mL) as described 
for 106 (105 °C, 72 h) to afford after purification by flash chromatography (hexanes:EtOAc 
7:3) 110 (27 mg, 0.10 mmol, 7%) as an orange oil. 1H NMR (400 MHz, chloroform-d) δ 7.83 
(d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.31 (t, J = 8.1 Hz, 1H), 5.41 (s, 1H), 5.07 (s, 1H), 
3.89 (t, J = 6.2 Hz, 2H), 2.88-2.67 (m, 2H). 
 3-(3-bromo-2-nitrophenyl)-3-buten-1-ol (112). 109 (231 mg, 0.66 
mmol) was reacted with 3-buten-1-ol (113 μL, 1.32 mmol), Pd(dba)2 (19 mg, 0.04 mmol), 
dppf (37 mg, 0.07 mmol), and urotropine (185 mg, 1.32 mmol) in DMA (5 mL) as described 
for 106 (105 °C, 72 h) to afford after purification by flash chromatography (hexanes:EtOAc 
7:3) 112 (12 mg, 0.04 mmol, 7%) as an orange oil as a mixture of isomers (1:11 by 1H NMR) 
and 3-bromo-2-nitrophenol (113, 75 mg, 0.34 mmol, 52%). Analytical data for the 1:11 
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mixture (data provided for compound 112): 1H NMR (400 MHz, chloroform-d, partial data) 
δ 5.33 (s, 1H), 5.19 (s, 1H), 3.69 (t, J = 6.0 Hz, 2H), 2.69-2.63 (m, 2H). 
3-bromo-2-nitrophenol (113). 109 (231 mg, 0.66 mmol) was reacted with 3-
buten-1-ol (113 μL, 1.32 mmol), Pd(dba)2 (19 mg, 0.04 mmol), dppf (37 mg, 0.07 mmol), and 
urotropine (185 mg, 1.32 mmol) in DMA (5 mL) as described for 106 (105 °C, 72 h) to afford 
after purification by flash chromatography (hexanes:EtOAc 7:3) 112 (12 mg, 0.04 mmol, 7%) 
as an orange oil as a mixture of isomers (1:11 by 1H NMR) and 113 (75 mg, 0.34 mmol, 52%). 
Analytical data for 113: 1H NMR (400 MHz, chloroform-d) δ 9.38 (br, s, 1H), 7.33-7.28 (m, 
2H), 7.15-7.08 (m, 1H).  
(S)-methyl-2-(tert-butylcarbonylamino)-4-(2-nitrophenyl)pent-4-
enoate (122). 105 (100 mg, 0.37 mmol) was reacted with 121 (170 mg, 0.74 mmol), 
Pd(dba)2 (21 mg, 0.04 mmol), dppf (25 mg, 0.04 mmol), and urotropine (104 mg, 0.74 mmol) 
in DMA (5 mL) as described for 106 (105 °C, 72 h) to afford after purification by flash 
chromatography (hexanes:EtOAc 7:3) an orange oil as a mixture of compounds (1.5:1 122 
and 123 (32%) : 105 (19%) by 1H NMR). Analytical data for the mixture of stereoisomers 
(data provided for compound 122): 1H NMR (400 MHz, chloroform-d) δ 8.18 (d, J = 8.5 Hz, 
1H), 7.94 (d, J = 8.0 Hz, 1H), 7.50-7.44 (m, 1H), 7.35 (d, J = 7.7 Hz, 1H), 5.28 (s, 1H), 5.14 (s, 
1H), 4.35 (d, J = 10.4 Hz, 1H), 3.58 (s, 3H), 3.01-2.90 (m, 1H), 2.77 (dd, J = 15.5, 7.9 Hz, 2H), 
1.41 (s, 9H). 
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(S)-methyl-2-(tert-butylcarbonylamino)-5-(2-
nitrophenyl)pent-4-enoate (123). 105 (100 mg, 0.37 mmol) was reacted with 121 (170 
mg, 0.74 mmol), Pd(dba)2 (21 mg, 0.04 mmol), dppf (25 mg, 0.04 mmol), and urotropine (104 
mg, 0.74 mmol) in DMA (5 mL) as described for 106 (105 °C, 72 h) to afford after purification 
by flash chromatography (hexanes:EtOAc 7:3) an orange oil as a mixture of compounds 
(1.5:1 122 and 123 (32%) : 105 (19%) by 1H NMR). Analytical data for the mixture of 
stereoisomers (data provided for compound 123): 1H NMR (400 MHz, chloroform-d, partial 
data) δ 6.96-6.77 (m, 1H), 6.14-6.01 (m, 1H), 4.58-4.44 (m, 1H), 3.78 (s, 3H), 2.71-2.58 (m, 
1H), 1.43 (s, 9H). 
3-ethanol-1H-indole (124). To a thick-walled pressure tube equipped with 
stir bar was added 106 (50 mg, 0.26 mmol), Pd(OAc)2 (5 mg, 0.02 mmol), and PPh3 (20 mg, 
0.06 mmol). A 2:1 mixture of MeOH:DMF (2 mL) was added, and the system was charged 
with 90 psi CO. The solution was heated to 60 °C and stirred vigorously for 24 h. The resulting 
solution was cooled to ambient temperature and extracted with EtOAc (3 x 5 mL). The 
combined organics were washed with H2O (2 x 5 mL), dried (MgSO4), and solvents were 
removed in vacuo. The resultant residue was purified via flash chromatography 
(hexanes:EtOAc 1:1) to afford 124 (31 mg, 0.19 mmol, 74%) as an off-white solid. 1H NMR 
(400 MHz, chloroform-d) δ 8.11 (br s, 1H), 7.63-7.58 (m, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.22-
7.17 (m, 1H), 7.12 (ddd, J = 7.9, 7.1, 0.9 Hz, 1H), 7.01 (d, J = 2.3 Hz, 1H), 3.88 (t, J = 6.4 Hz, 2H), 
3.05-2.97 (m, 2H), 1.71 (br s, 1H). 
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3-hexyl-1H-indole (126). 120 (49 mg, 0.21 mmol) was reacted with 
Pd(OAc)2 (5 mg, 0.02 mmol), and PPh3 (22 mg, 0.08 mmol) in CH3CN (3 mL) under 90 psi CO 
as described for 124 (100 °C, 24 h) to afford after purification by flash chromatography 
(hexanes:EtOAc 9:1) 126 (16 mg, 0.08 mmol, 37%) and unreacted starting material (120, 6 
mg, 0.03 mmol, 13%). Analytical data for 126: 1H NMR (400 MHz, chloroform-d) δ 7.87 (s, 
1H), 7.61 (d, J = 7.6 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.10 (t, J = 7.4 Hz, 
1H), 6.96 (s, 1H), 2.75 (t, J = 7.6 Hz, 2H), 1.71 (m, J = 7.6 Hz, 2H), 1.45-1.28 (m, 6H), 0.90 (m, 
3H); 13C NMR (101 MHz, chloroform-d) δ 136.3, 131.6, 127.6, 121.8, 120.9, 119.0, 117.2, 
111.0, 31.8, 30.1, 29.3, 25.1, 22.7, 14.1. 
N-tert-butoxycarbonyl-tryptophan methyl ester (127). The mixture 
of 122 with 123, with 105 (80 mg, ~0.23 mmol) was reacted with Pd(dba)2 (8 mg, 0.013 
mmol), dppp (5 mg, 0.013 mmol), 1,10-phenanthroline (5 mg, 0.03 mmol) in DMF (3 mL) 
under 90 psi CO as described for 124 (120 °C, 48 h) to afford after purification by flash 
chromatography (hexanes:EtOAc 7:3) two isolated compounds: 127 (16 mg, 0.05 mmol, 
22%) and 128 (7 mg, 0.02 mmol, 10%). Analytical data for 127: 1H NMR (400 MHz, 
chloroform-d) δ 8.16 (s, 1H), 7.55 (d, J = 7.4 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.19 (t, J = 7.3 
Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H), 7.02-6.98 (m, 1H), 5.09 (d, J = 7.8 Hz, 1H), 4.65 (d, J = 7.8 Hz, 
1H), 3.68 (s, 3H), 3.29 (s, 2H), 1.43 (s, 9H); 13C NMR (101 MHz, chloroform-d) δ 172.8, 155.2, 
136.0, 129.6, 122.7, 122.2, 119.6, 118.7, 111.1, 110.2, 79.8, 54.1, 52.2, 28.3, 27.9. 
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α-[[1,1-dimethylethoxy)carbonyl]amino]-1H-indole-2-
propanoic acid methyl ester (128). The mixture of 122 with 123, with 105 (80 mg, ~0.23 
mmol) was reacted with Pd(dba)2 (8 mg, 0.013 mmol), dppp (5 mg, 0.013 mmol), 1,10-
phenanthroline (5 mg, 0.03 mmol) in DMF (3 mL) under 90 psi CO as described for 124 (120 
°C, 48 h) to afford after purification by flash chromatography (hexanes:EtOAc 7:3) two 
isolated compounds: 127 (16 mg, 0.05 mmol, 22%) and 128 (7 mg, 0.02 mmol, 10%). 
Analytical data for 128: 1H NMR (400 MHz, chloroform-d) δ 8.31 (s, 1H), 7.53 (d, J = 8.8 Hz, 
1H), 7.32 (d, J = 7.8 Hz, 1H), 7.21 (d, J = 7.1 Hz, 2H), 6.28 (s, 1H), 5.13 (d, J = 8.5 Hz, 1H), 4.66 
(s, 1H), 3.76 (s, 3H), 3.29 (d, J = 4.1 Hz, 2H), 1.43 (s, 9H). 
1-oxide-4-quinolinecarbonitrile (141).  
Method A: A round-bottomed flask was charged with 140 (111 mg, 0.62 mmol) and 18-
crown-6 (49 mg, 0.19 mmol), and the system was purged with N2. THF (5 mL) was added via 
syringe, and the solution was cooled to -78 °C. A suspension of KOtBu (179 mg, 1.60 mmol) 
in THF (1 mL) was added slowly via syringe, followed by dropwise addition of acetaldehyde 
(346 μL, 6.17 mmol) via syringe. The resulting solution was stirred at -78 °C for 2 h. The 
reaction mixture was allowed to warm to ambient temperature and was quenched by slow 
addition of a saturated solution of NH4Cl (aq) and extracted with CH2Cl2 (3 x 10 mL). The 
combined organics were washed with brine (10 mL), dried (MgSO4), and solvents were 
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removed in vacuo. The resulting residue was purified by flash chromatography (EtOAc) to 
afford 141 (55 mg, 0.32 mmol, 47%) as a brown solid.  
Method B: A round-bottomed flask was charged with 140 (1.01 g, 6.17 mmol) and the system 
was purged with N2. THF (43 mL) was added via syringe, and the solution was cooled to -78 
°C. A suspension of KOtBu (2.07 g, 18.5 mmol) in THF (8.6 mL) was added slowly via syringe, 
followed by dropwise addition of acetaldehyde (3.46 mL, 61.7 mmol) via syringe. The 
resulting solution was stirred at -78 °C for 2 h. The reaction mixture was allowed to warm to 
ambient temperature and was quenched by slow addition of a saturated solution of NH4Cl 
(aq) and extracted with CH2Cl2 (3 x 20 mL). The combined organics were washed with brine 
(30 mL), dried (MgSO4), and solvents were removed in vacuo. The resulting residue was 
purified by flash chromatography (EtOAc) to afford 141 (698 mg, 4.10 mmol, 66%) as a 
brown solid. 
Analytical data for 141: 1H NMR (400 MHz, chloroform-d) δ 8.74 (dd, J = 8.6, 1.8 Hz, 1H), 8.50 
(d, J = 6.4 Hz, 1H), 8.23 (dd, J = 7.0, 2.6 Hz, 1H), 7.92-7.82 (m, 2H), 7.67 (d, J = 6.4 Hz, 1H). 
2-methyl-4-quinolinecarbonitrile (145). A round-bottomed flask was 
charged with 141 (36 mg, 0.21 mmol) and the system was purged with N2. THF (2 mL) was 
added via syringe, and the resulting solution was cooled to -30 °C. Methylmagnesium 
bromide (3.0M solution in THF, 71 μL, 0.21 mmol) was added via syringe, and the reaction 
mixture was stirred at -30 °C for 1 h. The solution was allowed to warm to ambient 
temperature and stirred for an additional 1 h, during which time the reaction mixture 
darkened in color. Upon completion, the reaction was quenched with H2O and extracted with 
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EtOAc (3 x 10 mL). The combined organics were dried (MgSO4) and solvents were removed 
in vacuo. The resulting residue was purified by flash chromatography (hexanes:EtOAc 1:1 to 
EtOAc) to afford 145 (24 mg, 0.14 mmol, 68%). 1H NMR (400 MHz, chloroform-d) δ 8.75 (d, 
J = 8.7 Hz,1H), 8.18 (d, J = 8.3 Hz, 1H), 7.86 (t, J = 7.9 Hz, 1H), 7.83-7.75 (m, 1H), 7.72 (s, 1H), 
2.70 (s, 3H). 
2-(2-methylpropyl)-4-quinolinecarbonitrile (146). A 2-necked round-
bottomed flask equipped with a cold-water condenser and addition funnel was charged with 
Mg (243 mg, 10.13 mmol) and I2 (crystals) and the system was purged with N2. The flask was 
heated until a purple vapor was visible. A solution of 1-bromo-2-methylpropane (1.0 mL, 
9.21 mmol) in THF (14 mL) was added via the addition funnel and the resulting solution was 
stirred at ambient temperature for 2 h to afford a solution of the desired Grignard reagent. 
A round-bottomed flask was charged with 141 (86 mg, 0.59 mmol) and the system was 
purged with N2. THF (4 mL) was added via syringe, and the solution was cooled to -30 °C. An 
aliquot of the Grignard solution (820 L, 9.0 mmol) was added via syringe, and the resulting 
solution was stirred at -30 °C for 1 h. The solution was allowed to warm to ambient 
temperature and stirred for an additional 1 h, during which time the reaction mixture 
darkened in color. Upon completion, the reaction was quenched with H2O and extracted with 
EtOAc (3 x 10 mL). The combined organics were dried (MgSO4) and solvents were removed 
in vacuo. The resulting residue was purified by flash chromatography (hexanes:EtOAc 7:3 
then EtOAc) to afford 146 (21 mg, 0.10 mmol, 17%) and recovered 141 (21 mg, 0.12 mmol, 
20%). 
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2-benzyl-4-quinolinecarbonitrile (147). 141 (200 mg, 1.18 mmol) was 
reacted with benzylmagnesium bromide (288 μL, 1.18 mmol) in THF (8 mL) as described for 
145 (-30 °C, 1 h, then ambient temperature, 1 h) to afford after purification by flash 
chromatography (hexanes:EtOAc 7:3 then EtOAc) 147 (6 mg, 0.02 mmol, 2%) and recovered 
141 (87 mg, 0.45 mmol, 44%). 1H NMR (400 MHz, chloroform-d) δ 8.78 (d, J = 8.7 Hz, 1H), 
8.22 (dd, J = 8.2, 4.1 Hz, 1H), 8.16 (d, J = 8.3 Hz, 1H), 7.90-7.83 (m, 1H), 7.83-7.76 (m, 1H), 
7.39 (d, J = 5.7 Hz, 3H), 7.31 (d, J = 6.9 Hz, 2H), 4.41 (s, 2H). 
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Figure 9: Ethyl 2-(2-nitrophenyl)-2-butenoate (10)—1H NMR 
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Figure 10: Ethyl 2-(2-nitrophenyl)-2-butenoate (10)—13C NMR 
 
 
 
 
 
 
 
 
 
103 
 
Figure 11: Ethyl 1-methoxyindole-3-carboxylate (12)—1H NMR 
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Figure 12: Ethyl 1-methoxyindole-3-carboxylate (12)—13C NMR 
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Figure 13: Ethyl 1-benzyloxyindole-3-carboxylate (13)—1H NMR 
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Figure 14: Ethyl 1-benzyloxyindole-3-carboxylate (13)—13C NMR 
 
 
 
 
 
 
 
 
 
107 
 
Figure 15: Methyl 1-(2-propen-1-yloxy)indole-3-carboxylate (14)—1H NMR 
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Figure 16: Methyl 1-(2-propen-1-yloxy)indole-3-carboxylate (14)—13C NMR 
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Figure 17: Methyl 1-methoxyindole-3-carboxylate (15)—1H NMR 
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Figure 18: Methyl 1-methoxyindole-3-carboxylate (15)—13C NMR 
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Figure 19: Ethyl 1-acetoxyindole-3-carboxylate (17)—1H NMR 
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Figure 20: Ethyl 1-acetoxyindole-3-carboxylate (17)—13C NMR 
 
 
 
 
 
 
 
 
 
113 
 
Figure 21: Ethyl 1-tosyloxyindole-3-carboxylate (18)—1H NMR 
 
 
114 
 
Figure 22: Ethyl 1-tosyloxyindole-3-carboxylate (18)—13C NMR 
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Figure 23: Ethyl 1-hydroxyindole-3-carboxylate (19)—1H NMR 
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Figure 24: Ethyl 1-hydroxyindole-3-carboxylate (19)—13C NMR 
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Figure 25: Ethyl 2-iodo-2-pentenoate (20)—1H NMR 
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Figure 26: Ethyl 2-iodo-2-pentenoate (20)—13C NMR 
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Figure 27: Ethyl 2-iodo-2-hexenoate (21)—1H NMR 
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Figure 28: Ethyl 2-iodo-2-hexenoate (21)—13C NMR 
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Figure 29: Ethyl 2-iodo-2-octenoate (22)—1H NMR 
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Figure 30: Ethyl 2-iodo-2-octenoate (22)—13C NMR 
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 Figure 31: Ethyl 2-iodo-2-nonenoate (23)—1H NMR 
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Figure 32: Ethyl 2-iodo-2-nonenoate (23)—13C NMR 
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Figure 33: Ethyl 3-cyclohexyl-2-iodopropenoate (24)—1H NMR 
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Figure 34: Ethyl 3-cyclohexyl-2-iodopropenoate (24)—13C NMR 
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Figure 35: Ethyl 2-iodo-4-phenylpentenoate (25)—1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
128 
 
Figure 36: Ethyl 2-iodo-4-phenylpentenoate (25)—13C NMR 
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Figure 37: Methyl 2-(2-nitrophenyl)-2-hexenoate (27)—1H NMR 
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Figure 38: Methyl 2-(2-nitrophenyl)-2-hexenoate (27)—13C NMR 
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Figure 39: Methyl 2-(6-methoxy-2-nitrophenyl)-2-butenoate (29)—1H NMR 
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Figure 40: Methyl 2-(6-methoxy-2-nitrophenyl)-2-butenoate (29)—13C NMR 
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Figure 41: Methyl 2-(5-methoxy-2-nitrophenyl)-2-butenoate (30)—1H NMR 
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Figure 42: Methyl 2-(5-methoxy-2-nitrophenyl)-2-butenoate (30)—13C NMR 
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Figure 43: Methyl 2-(4-methoxy-2-nitrophenyl)-2-butenoate (31)—1H NMR 
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Figure 44: Methyl 2-(4-methoxy-2-nitrophenyl)-2-butenoate (31)—13C NMR 
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Figure 45: Methyl 2-(3-methoxy-2-nitrophenyl)-2-butenoate (32)—1H NMR 
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Figure 46: Methyl 2-(3-methoxy-2-nitrophenyl)-2-butenoate (32)—13C NMR 
 
 
 
 
 
 
 
 
139 
 
Figure 47: Methyl 2-(5-carbomethoxy-2-nitrophenyl)-2-butenoate (33)—1H NMR 
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Figure 48: Methyl 2-(5-carbomethoxy-2-nitrophenyl)-2-butenoate (33)—13C NMR 
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Figure 49: Methyl 2-(4-carbomethoxy-2-nitrophenyl)-2-butenoate (34)—1H NMR 
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Figure 50: Methyl 2-(4-carbomethoxy-2-nitrophenyl)-2-butenoate (34)—13C NMR 
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Figure 51: Methyl 1-hydroxy-5-methoxyindole-3-carboxylate (35)—1H NMR 
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Figure 52: Methyl 1-hydroxy-5-methoxyindole-3-carboxylate (35)—13C NMR 
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Figure 53: Methyl 1,5-dimethoxyindole-3-carboxylate (36)—1H NMR 
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Figure 54: Methyl 1,5-dimethoxyindole-3-carboxylate (36)—13C NMR 
 
 
 
 
 
 
 
 
147 
 
Figure 55: Methyl 1-hydroxy-6-methoxyindole-3-carboxylate (37)—1H NMR 
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Figure 56: Methyl 1-hydroxy-6-methoxyindole-3-carboxylate (37)—13C NMR 
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Figure 57: Methyl 1,6-dimethoxyindole-3-carboxylate (38)—1H NMR 
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Figure 58: Methyl 1,6-dimethoxyindole-3-carboxylate (38)—13C NMR 
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Figure 59: Methyl 5-carbomethoxy-1-hydroxyindole-3-carboxylate (39)—1H NMR 
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Figure 60: Methyl 5-carbomethoxy-1-hydroxyindole-3-carboxylate (39)—13C NMR 
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Figure 61: Methyl 5-carbomethoxy-1-methoxyindole-3-carboxylate (40)—1H NMR 
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Figure 62: Methyl 5-carbomethoxy-1-methoxyindole-3-carboxylate (40)—13C NMR 
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Figure 63: Methyl 6-carbomethoxy-1-hydroxyindole-3-carboxylate (41)—1H NMR 
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Figure 64: Methyl 6-carbomethoxy-1-hydroxyindole-3-carboxylate (41)—13C NMR 
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Figure 65: Methyl 6-carbomethoxy-1-methoxyindole-3-carboxylate (42)—1H NMR 
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Figure 66: Methyl 6-carbomethoxy-1-methoxyindole-3-carboxylate (42)—13C NMR 
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Figure 67: 6-Amino-7-bromo-2,3-dihydro-5-methylinden-1-one (75)—1H NMR 
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Figure 68: 6-Amino-7-bromo-2,3-dihydro-5-methylinden-1-one (75)—13C NMR 
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Figure 69: N-(2,3-Dihydro-5-methyl-1-oxo-1H-inden-6-yl)acetamide (69)—1H NMR 
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Figure 70: N-(2,3-Dihydro-5-methyl-1-oxo-1H-inden-6-yl)acetamide (69)—13C NMR 
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Figure 71: N-(2,3-Dihydro-5-methyl-7-nitro-1-oxo-1H-inden-6-yl)acetamide (70)—1H 
NMR 
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Figure 72: N-(2,3-Dihydro-5-methyl-7-nitro-1-oxo-1H-inden-6-yl)acetamide (70)—13C 
NMR 
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Figure 73: 6-Amino-2,3-dihydro-5-methyl-7-nitroinden-1-one (71)—1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
166 
 
Figure 74: 6-Amino-2,3-dihydro-5-methyl-7-nitroinden-1-one (71)—13C NMR 
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Figure 75: 2,3-Dihydro-6-iodo-5-methyl-7-nitroinden-1-one (72)—1H NMR 
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Figure 76: 2,3-Dihydro-6-iodo-5-methyl-7-nitroinden-1-one (72)—13C NMR 
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Figure 77: 6-Bromo-2,3-dihydro-5-methylinden-1-one (76)—1H NMR 
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Figure 78: 6-Bromo-2,3-dihydro-5-methylinden-1-one (76)—13C NMR 
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Figure 79: 4-Bromo-2,3-dihydro-5-methylinden-1-one (77)—1H NMR 
 
 
172 
 
Figure 80: 4-Bromo-2,3-dihydro-5-methylinden-1-one (77)—13C NMR 
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Figure 81: 6-Bromo-2,3-dihydro-5-methyl-4-nitroinden-1-one (78)—1H NMR 
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Figure 82: 6-Bromo-2,3-dihydro-5-methyl-4-nitroinden-1-one (78)—13C NMR 
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Figure 83: 6-Bromo-2,3-dihydro-5-methyl-7-nitroinden-1-one (79)—1H NMR 
 
 
176 
 
Figure 84: 6-Bromo-2,3-dihydro-5-methyl-7-nitroinden-1-one (79)—13C NMR 
 
 
 
 
 
 
 
 
 
 
 
177 
 
Figure 85: 6-(3-hydroxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one (64)—1H 
NMR 
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Figure 86: 6-(3-hydroxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one (64)—13C 
NMR 
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Figure 87: 6-(3-methoxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one (81)—1H 
NMR 
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Figure 88: 6-(3-methoxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one (81)—13C 
NMR 
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Figure 89: 3-methoxy-5-(3-methoxy-1-propenyl)-6-methyl-4-nitroindene (83)—1H NMR 
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Figure 90: 3-methoxy-5-(3-methoxy-1-propenyl)-6-methyl-4-nitroindene (83)—13C NMR 
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Figure 91: 6-(1,2-epoxy-3-hydroxypropyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one 
(89)—1H NMR 
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Figure 92: 6-(1,2-epoxy-3-hydroxypropyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one 
(89)—13C NMR 
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Figure 93: 6,7-dihydro-2-(hydroxymethyl)-4-methylcyclopent[g]-(N-hydroxy)indol-
8(1H)-one (90)—1H NMR (DMSO-d6/CDCl3) 
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Figure 94: 6,7-dihydro-2-(hydroxymethyl)-4-methylcyclopent[g]-(N-hydroxy)indol-
8(1H)-one (90)—1H NMR (CDCl3) 
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Figure 95: 6,7-dihydro-2-(hydroxymethyl)-4-methylcyclopent[g]-(N-hydroxy)indol-
8(1H)-one (90)—13C NMR 
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Figure 96: 6,7-dihydro-2,4-dimethylcyclopent[g]indol-8(1H)-one (91)—1H NMR 
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Figure 97: 6,7-dihydro-2,4-dimethylcyclopent[g]indol-8(1H)-one (91)—13C NMR 
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Figure 98: Dilemmaone B (53)—1H NMR (CDCl3) 
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Figure 99: Dilemmaone B (53)—1H NMR (DMSO-d6) 
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Figure 100: Dilemmaone B (53)—13C NMR (DMSO-d6) 
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Figure 101: Dilemmaone B (53)—1H-15N gHSQCAD  
 
 
aFull 1H-15N gHSQCAD for 53. 
bExpansion of spectrum a. 
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Figure 102: Dilemmaone B (53)—gCOSY 
 
 
aFull gCOSY spectrum for 53. 
bExpansion of spectrum (a). 
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Figure 103: Dilemmaone B (53)—gHSQCAD (1JHC) 
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Figure 104: Dilemmaone B (53)—gHMBCAD Spectrum A 
 
 
 
 
 
 
 
 
197 
 
Figure 105: Dilemmaone B (53)—gHMBCAD Spectrum B 
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Figure 106: Dilemmaone B (53)—gHMBCAD Spectrum C 
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Figure 107: 6-(1,2-epoxy-3-methoxypropyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one 
(92)—1H NMR 
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Figure 108: 6-(1,2-epoxy-3-methoxypropyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one 
(92)—13C NMR 
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Figure 109: Dilemmaone A (52)—1H NMR (CDCl3) 
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Figure 110: Dilemmaone A (52)—1H NMR (DMSO-d6) 
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Figure 111: Dilemmaone A (52)—13C NMR (DMSO-d6) 
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Figure 112: Dilemmaone A (52)—1H-15N gHSQCAD 
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Figure 113: Dilemmaone A (52)—gCOSY 
 
aFull gCOSY spectrum for 52. 
bExpansion of spectrum (a). 
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Figure 114: 4-Amino-6-bromo-2,3-dihydro-5-methylinden-1-one (95)—1H NMR 
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Figure 115: 4-Amino-6-bromo-2,3-dihydro-5-methylinden-1-one (95)—13C NMR 
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Figure 116: 6-Bromo-2,3-dihydro-4-hydroxy-5-methylinden-1-one (96)—1H NMR 
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Figure 117: 6-Bromo-2,3-dihydro-4-hydroxy-5-methyl-7-nitroinden-1-one (97)—1H NMR 
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Figure 118: 3-(2-nitrophenyl)-3-buten-1-ol (106)—1H NMR 
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Figure 119: 4-(2-nitrophenyl)-3-buten-1-ol (107)—1H NMR 
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Figure 120: 3-(2-bromo-6-nitrophenyl)-3-buten-1-ol (110)—1H NMR 
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Figure 121: 3-(3-bromo-2-nitrophenyl)-3-buten-1-ol (112)—1H NMR 
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Figure 122: 3-bromo-2-nitrophenol (113)—1H NMR 
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Figure 123: (S)-methyl-2-(tert-butylcarbonylamino)-4-(2-nitrophenyl)pent-4-enoate 
(122)—1H NMR 
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Figure 124: (S)-methyl-2-(tert-butylcarbonylamino)-5-(2-nitrophenyl)pent-4-enoate 
(123)—1H NMR 
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Figure 125: 3-ethanol-1H-indole (124)—1H NMR 
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Figure 126: 3-hexyl-1H-indole (126)—1H NMR 
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Figure 127: 3-hexyl-1H-indole (126)—13C NMR 
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Figure 128: N-tert-butoxycarbonyl-tryptophan methyl ester (127)—1H NMR 
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Figure 129: N-tert-butoxycarbonyl-tryptophan methyl ester (127)—13C NMR 
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Figure 130: α-[[1,1-dimethylethoxy)carbonyl]amino]-1H-indole-2-propanoic acid methyl 
ester (128)—1H NMR 
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Figure 131: 1-oxide-4-quinolinecarbonitrile (141)—1H NMR 
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Figure 132: 2-methyl-4-quinolinecarbonitrile (145)—1H NMR 
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Figure 133: 2-benzyl-4-quinolinecarbonitrile (147)—1H NMR 
 
 
